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THE INVESTIGATION OF ANGIOGENIC MECHANISMS ASSOCIATED WITH
miRNA-126 SIGNALLING PATHWAY MOLECULES IN ATHEROSCLEROSIS
SUMMARY
Cardiovascular diseases are mainly the diseases of the blood vessels, the heart, and
the vascular diseases of the brain. The main types of cardiovascular diseases that
occur due to atherosclerosis include, ischaemic heart disease and coronary artery
disease, cerebrovascular diseases, peripheral artery disease and hypertensive heart
disease. According to the 2014 Global Status Report on Noncommunicable Diseases
published by World Health Organization, 38 million of the 56 million global deaths that
took place in 2012 occurred due to noncommunicable diseases, such as cardivascular
diseases, cancer, chronic respiratory diseases and diabetes. In 2012, cardiovascular
diseases, with a 31% of all global deaths, were the number one cause of death in the
world, based on World Health Organization data. 7.4 million of these cardiovascular
disease-related deaths took place because of coronary heart disease, while 6.7 million
were due to stroke. In Turkey, based on Turkish Statistical Institute Cause of
Death Statistics 2014 data, the leading cause of death was cardiovascular diseases,
represented with 40.4% of all national deaths that took place in 2014. Cardiovascular
diseases remain to be the leading cause of death in the world today. The underlying
pathological condition of cardiovascular diseases is atherosclerosis.
Although atherosclerosis is an irreversible process beginning with birth, the diseases
it causes can be prevented if major risk factors are taken into consideration. While
some of the major cardiovascular disease risk factors cannot be controlled, most of
them are treatable, controllable, or modifiable. The major cardiovascular disease risk
factors which cannot be changed are; increasing age, male gender and heredity, while
the treatable and modifiable ones include smoking, high blood cholesterol levels, high
blood pressure, physical inactivity, obesity and diabetes .
In this thesis study, samples from patients with carotid artery disease were studied.
Carotid endarterectomy is an operation, in which atherosclerotic plaques are surgically
removed from the carotid arteries of symptomatic patients with high grade stenosis
(≥ 60%). Carotid artery atherosclerotic plaque samples obtained from 14 patients
undergoing carotid endarterectomy for stenosis greater than 70% or stenosis ranging
from 50% to 70% associated to clinical symptoms were used in this thesis study.
Atherosclerosis is the chronic, progressive and immunoinflammatory disease of the
medium and large-size arteries. It is a complex disease which involves interactions
of multiple genetic and environmental factors. Starting with birth, atherosclerotic
process progresses slowly, causing diseases, such as coronary artery disease, stroke
and peripheral artery disease. In the inflammatory process of atherosclerosis, the inner
layer of arteries, the intima layer, gets thicker with lipid rich material (atheroma)
and connective tissue (sclerosis). According to the "Response to Injury" hypothesis
xix
of atherosclerosis, potential sources of injury, such as hyperlipidemia, hypertension,
metabolites, infections and mechanical factors such as shear stress are suggested to
cause the initiation of atherosclerosis. The pathological changes in atherosclerosis
occur due to molecular events of endothelial dysfunction, monocyte adherence and
entry into the vessel wall, monocyte development into foam cells, smooth muscle
cell migration and proliferation, advanced plaque formation with necrotic core and
neoangiogenesis, and thrombosis as a result of plaque rupture. Following rupture of a
vulnerable plaque, thrombus formation resulting in stroke or a myocardial infarction
causes deaths or disabilities. Atherosclerosis would possibly be a more benign disease
if thrombus formation could be prevented. The investigation of molecular mechanisms
resulting in angiogenesis in advanced plaques, a hallmark event of atherosclerosis, is
the main focus of this thesis study.
Angiogenesis is the process of new vessel formation from existing ones. The main
signalling pathways that control angiogenesis in cells are the vascular endothelial
growth factor (VEGF) pathway and Notch signalling. Intraplaque neoangiogenesis
has been linked with progressive atherosclerotic disease. The signalling pathways
contributing to angiogenesis represent potential targets for therapies aiming to prevent
intraplaque neoangiogenesis. This thesis study focuses on the role of angiogenic
mechanisms related to vascular endothelial growth factor pathway and the mechanisms
that interact with this pathway, such as microRNAs, the small, non-coding RNAs that
post-transcriptionally regulate many cellular processes, including angiogenesis. Egfl7,
a major player of angiogenesis that is expressed exclusively in embryonic and adult
vasculature, encodes two endothelial-specific miRNAs: miR 126-3p and miR 126-5p.
This thesis study was conducted with the aim of understanding the role of miR-126
signalling in angiogenesis and its contribution to disease progression. For this purpose,
the expression levels of miR 126-3p, the targets of miR 126-3p, miR 126-5p and Egfl7
were investigated in 14 human carotid artery atherosclerotic plaques and in control
samples.
The mRNA targets of miR 126-3p were investigated using the miRNA target
prediction databases, TargetScan and miRTarBase. Out of the vast number of miR
126-3p targets, Egfl7, Spred1 and Pik3r2 genes that were known to be involved
in angiogenesis as well as vascular endothelial growth factor signalling pathway
were chosen to be studied as targets of the miR 126-3p. Following the preliminary
bioinformatic research, total RNA and miRNA isolations were performed following
tissue homogenization procedures of 14 carotid artery atherosclerotic plaque and
control samples. Complementary DNA synthesis reactions were carried out and then
real time quantitative PCR reactions were performed to evaluate the relative expression
levels of Egfl7, Spred1, Pik3r2, miR 126-3p and miR 126-5p. It was expected to
observe Egfl7 and miR-126 up-regulation in carotid artery atherosclerotic plaques, due
to the vascular injury caused by progressive atherosclerosis, while the expression levels
of negative regulators of VEGF pathway, Spred1 and Pik3r2, were expected to be
down-regulated, since they are targeted by miR 126-3p.
For real time quantitative PCR analyses, relative quantification strategy employing
2∆∆CT model was used. All of the target gene and miRNA expression levels of plaque
samples were compared to those of control samples and normalized to the levels of
the 18S ribosomal RNA and U6 small nuclear RNA endogenous controls. Following
data analyses, statistical analyses were performed. The significance of differences
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between the results from plaque and control tissues was examined with Student’s t
test. Demographic information was compared with gene expression data expressed as
fold change by using Chi-square and Fisher’s Exact tests.
In accordance with the hypothesis, miR 126-3p expression was higher in 11 out of
14 atherosclerotic plaque samples compared to plaque adjacent controls. Spred and
Pik3r2 were down-regulated in 8 and 9 samples compared to controls, respectively.
Considering the overall gene expression levels, miR 126-3p was up-regulated by 2.14
fold in plaques in comparison to controls (p <0.05). MiR 126-5p was found to be
up-regulated in 8 patient plaque samples compared to controls, while down-regulation
was observed in 6 of the patient samples. Considering the overall expression,
miR 126-5p expression was higher in plaques compared to control samples. Egfl7
up-regulation was observed in 11 plaque samples out of 14. The overall Egfl7 mRNA
expression was higher in plaques (p <0.001) compared to controls.
This thesis study provides the first evidence on miR 126-3p expression in deep
intraplaque regions. To the knowledge, the expression levels of miR 126-3p,
its targets Spred1, Pik3r2, miR 126-5p and Egfl7 in atherosclerotic plaques from
human carotid arteries were evaluated for the first time. This work, supported
by data on expression levels of miR 126-5p, miR 126-3p and its targets Spred1,
Pik3r2 and Egfl7, demonstrates the contribution of miR-126 signalling molecules and
neoangiogenesis driven by these molecules to atherosclerotic plaque progression in
advanced atherosclerosis, despite their known atheroprotective roles in endothelial
progenitor cells. The results of this thesis study constitutes preliminary bases
for future miRNA biomarker studies to be used in monitoring plaque progression
and intraplaque neoangiogenesis, as well as miRNA based therapies for preventing
intraplaque neoangiogenesis, therefore thrombosis. In addition, Egfl7 can be
considered as a promising prognostic marker of intraplaque neoangiogenesis, to
aid in monitoring the unstable plaques, as well as preventing vulnerable plaque
rupture. Egfl7 based anti-angiogenic therapy could be offered as a strategy
in eliminating intraplaque neoangiogenesis and stabilization of plaques that are
prone to rupture, therefore preventing the devastating consequences of advanced
atherosclerosis. The molecular mechanisms of miR 126-modulated dysregulation need
further investigation, particularly on the phosphorylation status of the downstream
signalling molecules, to be able to fully grasp the affect of miR-126 on vascular
endothelial growth factor regulated angiogenesis in atherosclerosis. The interaction of
miR-126 with other miRNAs and signalling molecules needs to be elucidated. To be
able to fully understand the roles of angiogenesis in different stages of atherosclerosis,
the study of patient samples considering the different degrees of stenosis is suggested.
Furthermore, larger scale studies must be performed on more than one arterial system,
with the aim of determining the specific regulation of angiogenesis by miRNAs in
different arterial systems. The potential use of miRNAs as biomarkers to monitor
plaque neoangiogenesis and disease progression, as well as the development of
miRNA-based therapies are promising areas of research in the battle against the fatal
consequences of atherosclerosis.
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ATEROSKLEROZDA miRNA-126 SI˙NYAL YOLAG˘I MOLEKÜLLERI˙ I˙LE
I˙LI˙S¸KI˙LI˙ ANJI˙YOGENI˙K MEKANI˙ZMALARIN ARAS¸TIRILMASI
ÖZET
Kardiyovasküler hastalıklar, kalp ve kalp damarlarının, beyin damarlarının ve
vücuttaki tüm dig˘er damarların hastalıkları olarak tanımlanırlar. Ateroskleroza bag˘lı
olarak ortaya çıkan kardiyovasküler hastalıklar arasında, koroner arter hastalıkları,
serebro-vasküler hastalıklar, periferal arter hastalıg˘ı ve hipertansif kalp hastalıg˘ı
bulunmaktadır. Dünya Sag˘lık Örgütü tarafından 2014 yılında yayınlanan Kalp ve
Damar Hastalıklarını Önleme ve Kontrolü Küresel Atlası verilerine göre, dünyada
2012 yılında gerçekles¸mis¸ olan 56 milyon ölümün 38 milyonu kardiyovasküler
hastalıklar, kanser, kronik solunum yolu hastalıkları ve diyabet gibi bulas¸ıcı olmayan
hastalıklar nedeniyle meydana gelmis¸tir. 2012 yılında kardiyovasküler hastalıklar
nedenli ölümler, tüm dünyada birincil ölüm nedeni olup, tüm ölümlerin % 31’ini
olus¸turmus¸tur. Tüm kardiyovasküler hastalıklar ile ilis¸kili ölümlerin 7.4 milyonu
koroner arter hastalıg˘ına bag˘lı olarak, 6.7 milyonu ise inme nedenli gerçekles¸mis¸tir.
Türkiye I˙statistik Kurumu tarafından yayınlanan Ölüm Nedeni I˙statistikleri 2014
verilerine göre, kardiyovasküler hastalık kaynaklı ölümler, 2014 yılında gerçekles¸mis¸
olan tüm ölümlerin %40.4’ünü olus¸turarak, birincil ölüm sebebini tes¸kil etmis¸tir.
Günümüzde hala tüm dünyadaki bir numaralı ölüm nedeni olan kalp ve damar
hastalıklarının altında yatan temel mekanizma aterosklerozdur.
Ateroskleroz dog˘umla bas¸layan geri dönüs¸süz bir süreç olsa da, ana risk faktörleri
göz önüne alındıg˘ında, aterosklerozun yol açtıg˘ı kardiyovasküler hastalıklar büyük
ölçüde önlenebilmektedir. Kalp ve damar hastalıg˘ı risk faktörlerinin bazıları deg˘is¸tir-
ilememektedir, ancak büyük çog˘unlug˘u kontrol edilebilmekte, tedavi edilebilmekte
veya modifiye edilebilmektedir. Deg˘is¸tirilemeyen veya kontrol edilemeyen risk
faktörlerinin bas¸ında ileri yas¸, erkek cinsiyet ve genetik etmenler gelmektedir. Öte
yandan, yüksek kolesterol seviyeleri, hipertansiyon, obezite, diyabet, sigara kullanımı
ve fiziksel inaktivite gibi risk faktörleri tedavi edilebilir ve modifiye edilebilir risk
faktörleri olarak deg˘erlendirilmektedir.
Bu tez çalıs¸masında, karotis arter hastalarından elde edilmis¸ olan aterosklerotik plak
örnekleri kullanılmıs¸tır. Ateroskleroza bag˘lı ortaya çıkan arter hastalıg˘ı, beyine kan
götüren damarlar olan karotis arterlerdeki kan akıs¸ının tıkanıklıg˘a bag˘lı azalması
sonucu meydana gelir. Beyindeki belirli bir bölgeye, karotis arterlerdeki tıkanıklıg˘a
bag˘lı olarak kan akıs¸ı azaldıg˘ında, o bölgede fonksiyon kaybı ve buna bag˘lı olarak
geçici iskemik atak olarak isimlendirilen semptomlar ortaya çıkar. Görme kaybı
(Amaurosis fugax), konus¸mada bozukluklar, ekstremitelerde güçsüzlük hissi ve yüzde
duyu kaybı bu semptomlardan bazılarını olus¸turmaktadır. Beyindeki bir bölgeye
kan akıs¸ı aniden kesildig˘inde ise inme olarak adlandırılan durum meydana gelir.
Karotis arter hastalıg˘ının tes¸hisi için, ultrason ve manyetik rezonans anjiyogram
gibi görüntüleme tekniklerinden yararlanılmaktadır. Bu testler sayesinde, karotis
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arterlerde meydana gelen daralmanın, bir dig˘er deyis¸le, stenozun varlıg˘ı ve derecesi
belirlenebilir. Asemptomatik ve semptomatik karotis arter hastalıg˘ının ayrımı önem
tas¸ımaktadır. Asemptomatik hastalıkta, geçici iskemik ataklar veya inme olmaksızın,
proksimal internal karotis arterde % 50–60 stenoz gözlemlenir. Asemptomatik
hastalıg˘ın ilerleyis¸ini önlemek amacıyla, hipertansiyon, Diyabet ve yüksek kolesterol
gibi risk faktörlerinin tedavisi gibi invazif olmayan terapiler uygulanmaktadır. I˙leri
derecede stenozun (≥ %60) tedavisi için ise, karotis endarterektomisi ve karotis
arterlere stent yerles¸tirilmesi gibi invazif terapiler tercih edilmektedir. Karotis
endarterektomi operasyonu semptomatik hastalarda gelecek inme riskinin azaltılması
amacıyla gerçekles¸tirilir. Bu cerrahi operasyon ile karotis arterlerde daralmaya neden
olan aterosklerotik plaklar çıkartılır. Bu çalıs¸mada, karotis arterlerinde %70’den
daha yüksek derecede veya %50 ile %70 arasında deg˘is¸en darlık bulunan 14 adet
semptomatik hastadan endarterektomi esnasında çıkartılan aterosklerotik plaklar ve
plak etrafındaki bölgeden elde edilen kontrol dokuları kullanılmıs¸tır.
Ateroskleroz, orta ve büyük çaplı arterlerin kronik, dejeneratif, immun-enflamatuvar
hastalıg˘ıdır. Pek çok genetik etmen ve çevresel etmenin etkiles¸imini içeren kompleks
bir hastalık olarak tanımlanır. Dog˘um ile bas¸layan aterosklerotik süreç, yavas¸
ilerleyerek, özellikle 40 ve 50 yas¸ sonrasında koroner arter hastalıg˘ı, inme ve periferal
arter hastalıg˘ı gibi rahatsızlıklara neden olur. Ateroskleroz enflamasyonun çok etkin
oldug˘u bir süreç olup, arterlerin en iç tabakası olan intima tabakasının kalınlas¸ması
sonucu olus¸an lipid bakımından zengin materyal (aterom) ve konnektif doku (skleroz)
ile karakterizedir. Aterosklerotik süreci açıklamaya yönelik gelis¸tirilmis¸ olan
hipotezler arasında bulunan ve yaygın kabul gören "Hasara tepki" hipotezine göre,
hiperlipidemi, hipertansiyon, çes¸itli metabolitler, enfeksiyonlar ve mekanik faktörler
gibi potansiyel kaynaklar endotel hasarına sebep olarak aterosklerotik süreci bas¸latır-
lar. Ateroskleroz patogenezinde yer alan temel basamaklar, endotel disfonksiyonu,
LDL kolesterolün oksidasyonu, monositlerin damar duvarına yapıs¸ması ve damar
duvarından içeriye giris¸leri, monositlerin makrofajlara farklılas¸ması ve makrofajların
okside-LDL partiküllerini fagosite etmeleri sonucu köpük hücre olus¸umu, düz kas
hücrelerinin intima tabakasına göç etmeleri ve proliferasyonları sonucu fibröz bas¸lık
olus¸umu, ilerlemis¸ lezyonlardaki makrofajların apoptozuna bag˘lı olarak plak nekrotik
çekirdeg˘inin olus¸umu, plak içerisinde neoanjiyogenez ve plag˘ın yırtılması ile trombüs
olus¸umu olarak sıralanabilir. Kararsız plakların yırtılması sonucunda olus¸an trombüs,
inme ve miyokard enfarktüsü gibi durumlara ve bu durumlara bag˘lı olan sakatlıklara
ve ölümlere yol açmaktadır. Trombüs olus¸umu engellenebilir oldug˘u taktirde
aterosklerozun çok daha iyi huylu seyreden bir hastalık olacag˘ı pek çok çalıs¸mada
önerilmektedir. I˙lerlemis¸ aterosklerotik plakların içerisindeki yeni damar olus¸umuna
yol açan moleküler mekanizmaların aras¸tırılması, bu tez çalıs¸masının odak noktasını
olus¸turmaktadır.
Anjiyogenez, var olan damarlardan yeni damar olus¸umudur. Hücrelerde anjiyogenezi
kontrol eden temel sinyal yolakları vasküler endoteliyal büyüme faktörü yolag˘ı ve
Notch sinyal yolag˘ıdır. Aterosklerotik plak içi anjiyogenezin aterosklerozun ilerleyis¸i
ile olan ilis¸kisi pek çok çalıs¸ma ile gösterilmis¸tir. Bu nedenle, anjiyogenezle ilis¸kili
olan sinyal yolakları, plak içi anjiyogenezi önlemeyi amaçlayan terapiler için hedef
tes¸kil etmektedirler. Bu tez çalıs¸ması, vasküler endoteliyal büyüme faktörü yolag˘ı
ile ilis¸kili anjiyogenik mekanizmaların rolünün ve mikroRNAlar gibi, bu yolak ile
etkiles¸imde bulunan moleküllerin aras¸tırılmasını amaçlamaktadır.
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MikroRNAlar (miRNAlar) küçük, tek-iplikçikli RNA molekülleridir. Genellikle
18-22 nukleotid uzunlug˘unda olan ve kodlama yapmayan bu RNAlar, gen anlatımını
transkripsiyon sonrası seviyede düzenleyen önemli regülatör moleküller olarak görev
yaparlar. MiRNAlar pek çok önemli biyolojik fonksiyon ve hücresel olayda görev
alırlar. MiRNAların görev yaptıkları önemli hücresel prosesler arasında hücre
proliferasyonu, metabolizma, apoptoz, senesens, tümör olus¸umu, damar olus¸umu ve
gelis¸im gelmektedir. Anjiyogenezde çok önemli rolü olan ve hem embriyonik hem de
yetis¸kin damar sisteminde anlatımı yapılan Egfl7, endotele spesifik iki adet mikroRNA
olan miR 126-3p ve miR 126-5p’yi intronundan kodlar. MiR-126 sinyal yolag˘ının
anjiyogenezdeki rolünü ve ateroskleroz patogenezine katkısını ortaya çıkarmak amacı
ile gerçekles¸tirilen bu çalıs¸mada, miR 126-3p ve hedef genleri ile miR 126-5p ve
Egfl7’nin ekspresyon seviyeleri 14 adet karotis arter aterosklerotik plak dokusu ve 14
adet kontrol dokusunda incelenmis¸tir.
Mir 126-3p hedef genleri miRNA hedef tahmin veritabanları olan TargetScan and
miRTarBase kullanılarak elde edilmis¸, elde edilen bilgiler ve literatür aras¸tırması
sonucunda anjiyogenezde rolü olan ve vasküler endoteliyal büyüme faktörü sinyal
yolag˘ının negatif regülatörleri olan Spred1 and Pik3r2 genleri ile Egfl7’nin çalıs¸ılacak
miR 126-3p hedef genleri olarak seçilmesine karar verilmis¸tir. Ön biyoinformatik
aras¸tırmayı takiben, 14 adet karotis arter aterosklerotik plak ve kontrol dokusunun
homojenizasyonu ve sonrasında elde edilen homojenizatlardan total RNA ve miRNA
izolasyonları gerçekles¸tirilmis¸tir. RNA izolasyonları sonucunda elde edilen total
RNA ve miRNA’ların konsantrasyonları ve saflıkları spektrofotometrik yöntemle
belirlenmis¸, ve RNA miktarları es¸itlenerek komplementer DNA (cDNA) reaksiyonları
gerçekles¸tirilmis¸tir. Elde edilen cDNA’lar kullanılarak gerçek zamanlı kantitatif PZR
reaksiyonları yürütülmüs¸ ve bu sayede plak ve kontrol dokularındaki Egfl7, Spred1,
Pik3r2, miR 126-3p ve miR 126-5p rölatif ekspresyon seviyeleri ölçülmüs¸tür.
Gerçek zamanlı kantitatif PZR analizleri için, 2∆∆CT modelinin kullanıldıg˘ı rölatif
kantifikasyon stratejisinden yararlanılmıs¸tır. Plak örneklerindeki tüm hedef gen ve
miRNA ekspresyon seviyeleri kontrol örneklerindeki hedef gen ve miRNA seviyeleri
ile kars¸ılas¸tırılmıs¸ ve 18S ribozomal RNA (hedef genler için) ve U6 küçük nüklear
RNA (miRNAlar için) endojen kontrolleri kullanılarak normalizasyon yapılmıs¸tır.
Data analizlerini takiben, istatistiksel analizler gerçekles¸tirilmis¸tir. Plak ve kontrol
dokularından elde edilen sonuçlar arasındaki farkın istatistiksel anlamlılıg˘ı Student’s t
test ile aras¸tırılmıs¸tır. Kat farkı olarak ifade edilen gen ekspresyon verileri, hastaların
demografik ve klinik bilgileri ile kars¸ılas¸tırılmıs¸tır. Bu analizler için Chi-square ve
Fisher’s Exact testleri kullanılmıs¸tır.
Bu çalıs¸mada, literatürden elde edilen bilgiler derlenerek, ilerlemis¸ aterosklerotik
hastalıg˘a bag˘lı olarak görülen anjiyogenez nedeni ile, Egfl7 ve miR 126-3p ile
miR 126-5p’nin karotis arter aterosklerotik plaklarında, kontrollere göre up-regüle
olacag˘ı, buna kars¸ılık miR 126-3p hedef genleri olan Spred1 ve Pik3r2’nin ekspresyon
seviyelerinin plaklarda kontrollere göre azalmıs¸ olacag˘ı hipotezi ortaya konulmus¸tur.
Sonuçlara bakıldıg˘ında, beklendig˘i üzere miR 126-3p ekspresyon seviyelerinin 11 adet
plak örneg˘inde, kontrollere göre yüksek oldug˘u bulunmus¸, miR 126-3p hedef genleri
olan Spred ve Pik3r2’nin ekspresyon seviyelerinin kontrollere göre 8 ve 9 adet plak
örneg˘inde daha düs¸ük oldug˘u gözlemlenmis¸tir. Genel ekspresyon seviyesi göz önüne
alındıg˘ında, miR 126-3p’nin plaklardaki ekspresyonunun, kontrollere göre 2.14 kat
arttıg˘ı bulunmus¸tur (p <0.05). I˙ncelenmis¸ olan dig˘er miRNA miR 126-5p’nin 8 adet
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plak örneg˘inde kontrollere göre up-regüle oldug˘u gözlemlenmis¸tir. Genel ekspresyon
seviyesine bakıldıg˘ında ise plaklarda kontrollere göre yüksek bulunan ekspresyon
seviyesi, istatistiksel anlamlılıg˘a ulas¸amamıs¸tır. Ek olarak, 11 adet plak örneg˘inde,
kontrollere göre Egfl7’nin up-regule oldug˘u bulunmus¸, genel ekspresyon seviyesine
bakıldıg˘ında ise Egfl7 ekspresyonunun plaklarda kontrollere göre daha yüksek oldug˘u
gözlemlenmis¸tir(p <0.001).
Bu tez çalıs¸ması, derin plak-içi miR 126-3p ekspresyonu seviyelerininin aras¸tırılması
açısından bir ilk nitelig˘i tas¸ımaktadır. Literatürde miR 126-3p, hedef genleri Spred1,
Pik3r2, miR 126-5p ve Egfl7 ekspresyon seviyelerini insan karotis arter aterosklerotik
plaklarında aras¸tıran bas¸ka bir çalıs¸maya rastlanmamıs¸tır. MiR 126-3p, hedef genleri
Spred1, Pik3r2, miR 126-5p ve Egfl7 ekspresyon seviyesi verileri ile desteklenen
bu tez çalıs¸masında, miR-126 sinyal yolag˘ı moleküllerinin ve bu moleküllerce
desteklenen neoanjiyogenezin ileri seviye aterosklerozda gözlemlenen aterosklerotik
plakların gelis¸imine katkısı gösterilmektedir. Bu tez çalıs¸ması, aterosklerotik
plak gelis¸iminin ve plak içi neoanjiyogenezin takibi konusunda yapılacak gelecek
miRNA biyobelirteç çalıs¸maları açısından ve plak içi neoanjiyogenezin, dolayısıyla
trombüs olus¸umunun önlenmesi konusunda yapılacak gelecek miRNA tabanlı terapiler
açısından bir ön çalıs¸ma çalıs¸ması nitelig˘indedir. Ek olarak, Egfl7 de kararsız
plakların takibi ve bu plakların yırtılmasının engellenmesi konularında kullanılabilecek
gelecek vaad eden prognostik bir biyobelirteç olarak deg˘erlendirilebilir. Egfl7 tabanlı
anti-anyijogenik terapiler, plak içi neoanjiyogenezin elimine edilmesi ve yırtılmaya
meyilli plakların stabil halde getirilmesinde bir strateji olarak önerilmektedir.
MiR-126 tabanlı gen regülasyonunun moleküler mekanizmaları, miR-126’nın
vasküler endoteliyal büyüme faktörü ile regüle edilen anjiyogenezdeki etkisinin
tam olarak anlas¸ılabilmesi amacı ile, özellikle vasküler endoteliyal büyüme faktörü
yolag˘ında yer alan moleküllerinin fosforilasyon durumlarının da inceleneceg˘i, daha
genis¸ aras¸tırmalar ile ortaya konulmalıdır. Mir-126’nın dig˘er miRNAlar ve
sinyal yolag˘ı molekülleri ile olan etkiles¸imi açıg˘a çıkarılmalıdır. Anjiyogenezin
aterosklerozun deg˘is¸ik evrelerindeki farklı rollerini daha iyi anlayabilmek amacı ile,
farklı arteriyel stenoz derecesine sahip hastalardan alınacak örneklerde çalıs¸malar
yapılması önerilmektedir. Bununla beraber, farklı arteriyel sistemlerde görülen
hastalıkların benzerlik ve farklılıklarının ortaya konulması ve tüm sistemlerde ortak
olan bir regülasyonun belirlenebilmesi için, karotis ve koroner arter hastalarından
alınacak örneklerin kullanılacag˘ı, daha genis¸ çapta yapılacak miRNA profillemesi
çalıs¸malarının faydalı olacag˘ı düs¸ünülmektedir.
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1. INTRODUCTION
1.1 Purpose of Thesis
Cardiovascular diseases, mainly described as the diseases of the blood vessels, the
heart, and the vascular diseases of the brain, were the number one cause of death among
all the deaths attributable to noncommunicable diseases in 2014 [1, 2]. Unfortunately,
the devastating consequences of the coronary artery disease and carotid artery disease,
such as the myocardial infarction and stroke, remain to be the leading causes of death
and disability in the world today. The underlying pathology of cardiovascular diseases
is atherosclerosis [3, 4].
In the pathological process of atherosclerosis, the walls of medium and large sized
arteries are thickened and hardened. Atherosclerosis is characterized by lipid
accumulation and plaque formation in the arteries [5, 6]. Once the disease is clinically
manifested as coronary heart disease [7], cerebrovascular disease or peripheral artery
disease, many therapies to prevent complications are applied. Since atherosclerosis is
a condition that is driven mostly by lipoproteins [7], drug therapies aiming to lower
blood cholesterol levels, known as statins have been developed. Besides statins,
anti-hypertensive drugs are also used, since hypertension is one of the major risk
factors of cardiovascular diseases. Anti-coagulants are widely used as well. Also,
drug therapies to increase levels of high density lipoprotein exist [8]. Collectively,
these drug therapies are known as primary protection [6, 9]. But, drug therapies have
side effects and they are not cost effective. Traditionally, angiography is used to
monitor the progression of atherosclerosis. In addition, new imaging techniques such
as magnetic resonance imaging, computed tomography, positron emission tomography,
ecocardiography and intravascular ultrasound are used as well [10, 11]. But, although
atherosclerotic plaques can be detected by means of these imaging technologies,
most of the people with atherosclerotic plaques in their arteries do not develop
disease [9]. Finally, surgical interventions, such as coronary angioplasty, coronary
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artery bypass grafting and carotid endarterectomy are used for the treatment of
atherosclerotic cardiovascular diseases. They are considered as invasive, expensive
and high risk methods [12]. Detecting atherosclerosis early is very important in
preventing cardiovascular diseases. For this purpose, biomarkers that would detect
the early lesions of atherosclerosis as well as biomarkers that would enable physicians
to monitor the progress of plaques are needed.
Atherosclerosis is a process starting with birth and it progresses throughout life. The
earliest lesions of atherosclerosis, known as fatty streaks, are known to be reversible
partially [13], but once the disease starts to progress further, more advanced lesions
are observed. The rupture of the complex, unstable plaques, which are known as
vulnerable plaques, result in thrombus formation [6, 14]. Atherosclerosis itself is
not the cause of death. The narrowing of the arteries due to plaque formation cause
obstruction of blood flow to the brain, the heart and the limbs [7]. Following rupture
of a vulnerable plaque, it is the thrombus formation resulting in stroke or a myocardial
infarction that causes death. Therefore, atherosclerosis would possibly be a more
benign disease if thrombus formation could be prevented. From this point of view,
why atherosclerotic plaques develop is not the question for research purposes anymore.
The crucial question is why only few of the many plaques within a given person
undergoes the thrombosis-prone phase during lifespan. To be able to prevent the
development of vulnerable plaques, as well as finding and treating them is the main
focus of atherosclerosis research [14].
The exact molecular mechanisms of how asymptomatic lesions become vulnerable
plaques are yet to be elucidated. Intraplaque neoangiogenesis has been linked with
progressive atherosclerotic disease and the development of acute lesion instability
by many studies [15]. Neoangiogenesis is suggested to cause stenosis, intraplaque
hemorrage, thrombosis and consequently a stroke or a heart attack. The signalling
pathways contributing to angiogenesis represent potential targets for therapies aiming
to prevent intraplaque neoangiogenesis [16,17]. This thesis study focuses on the role of
angiogenic mechanisms related to vascular endothelial growth factor (VEGF) pathway,
the main driver of angiogenesis in cells, as well as mechanisms that interact with the
VEGF pathway, such as microRNAs.
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MicroRNAs (MiRNAs), the small, non-coding RNAs that post-transcriptionally
regulate many cellular processes are widely studied in cardiovascular diseases and
atherosclerosis [18]. Egfl7, a major player of angiogenesis that is expressed exclusively
in embryonic and adult vasculature, encodes two endothelial-specific miRNAs: miR
126-3p and its passanger strand, miR 126-5p.
The present study aims to understand the role of miR 126 signalling in angiogenesis.
This study was designed to answer the following questions:
•What are the expression levels of miR 126-3p, of miR 126-3p targets, miR 126-5p
and Egfl7 in human carotid artery atherosclerotic plaques relative to control samples?
•Are the clinical parameters (cardiovascular disease risk factors) of the patients
correlated with relative gene expression levels?
• Through which mechanisms does intraplaque neoangiogenesis affect atherosclerotic
disease?
The outcomes of this thesis work are believed to provide useful information on the
roles of miR 126-3p and -5p as well as their target partners in angiogenesis and
atherosclerosis. A better understanding of the VEGF pathway and its interaction
with miR 126 can possibly lead to development of drugs targeting neoangiogenesis.
The results of the conducted expression study of these genes and miRNAs may
constitute preliminary bases for future miRNA biomarker studies for monitoring
plaque progression and intraplaque neoangiogenesis, as well as miRNA based
therapies for preventing intraplaque neoangiogenesis, therefore thrombosis.
1.2 Cardiovascular System
There are three basic components in a cardiovascular system: a muscular pump,
such as the heart, a circulatory fluid, and a set of interconnecting vessels. In a
closed circulatory system, such as the cardiovascular system of humans and other
vertebrates, the circulatory fluid is blood [19]. The cardiovascular system transports
fluids throughout the body, connecting the aqueous environment of the cells to the
organs that function in gas exchange, absorption of nutrients, and disposal of wastes
[20]. Before reaching the blood, O2 inhaled from air diffuses across two layers of cells
in the lungs. Then, the oxygen-rich blood is carried to the rest of the body by the
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help of the cardiovascular system. As the blood flows throughout the tissues via blood
vessels, O2 in the blood reaches the cells by diffusion. One of the benefits of a closed
circulatory system is the relatively high blood pressure, that effectively delivers of O2
and nutrients to the cells [19–21].
Together, the heart, the blood vessels (or vasculature), the cells and plasma of the
blood construct the human cardiovascular system [19]. The heart, located behind the
sternum, is an organ about the size of a fist, composed of cardiac muscle called the
myocardium mostly [20]. A system of coronary arteries feed the the heart muscle with
blood supply. The two atria of the heart function as collection chambers for blood
returning to the heart from the systemic circulation or the lungs. The function of the
heart is to pump the blood from its atria into large vessels branching into smaller ones
which end up infiltrating the organs [19–21].
Figure 1.1 : The model of the cardiovascular system [20].
The circulation of blood to and from the heart occurs through an extensive network of
vessels. The three main types of blood vessels of the vasculature are the arteries, veins,
and capillaries. The blood flows in vessels in one direction. A system of valves in the
heart and veins ensures that the blood flow is confined to one direction. Arteries carry
the blood to organs where they branch and form smaller vessels called arterioles that
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work as outlets with high resistance for arterial blood flow, directing the distribution of
blood flow to tissues. Arterioles can adjust their diameter by selectively constricting
and dilating. The alterations of the diameter are regulated via autonomous nervous
system, hormones and local factors such as tissue oxygen concentration. Blood passes
from the arterioles to the capillaries, the microscopic vessels with very thin, leaky
walls. Capillaries form a network known as capillary beds and infiltrate every tissue.
The porous epithelium of the capillaries allows the exchange of chemicals, including
dissolved gases, by diffusion between the interstitial fluid surrounding cells of the
tissues and the blood. As demonstrated in Figure 1.1, at their distal ends, capillaries
come together to form venules, which further converge into veins, carrying the blood
back to the heart [19–23].
The cardiovascular system is composed of two circuits, known as a double circulation.
The double circulation arrangement includes the systemic circulation and the
pulmonary circulation, which are combined in one single organ, the heart. The
blood returning from the organs, deprived of oxygen, enters the right atrium of the
heart [22, 23].
Figure 1.2 : The anatomy of the human heart [24].
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From the right atrium, passing through the tricuspid valves, the blood moves to the
right ventricle, from where it is pumped into the pulmonary arteries. The pulmonary
arteries carry the oxygen deprived blood to the lungs to become oxygenated in the
capillaries of the lungs. Then, the blood is carried back to the left atrium of the
heart via the pulmonary veins, completing the pulmonary circuit part of the double
circulation. As the heart muscle contracts, blood is pumped into the left ventricle
through the bicuspid or mitral valves. From the left ventricle, the blood is sent into
the aorta, through the aortic valves. Starting in the heart and ending in the abdomen,
the aorta is the largest vessel in the body. The aorta branches into systemic arteries
and smaller arterioles and finally into capillary beds in organs and tissues to transport
the blood from the left ventricle to every organ throughout the body. In the capillary
beds, exchange of oxygen with carbon dioxide takes place. The systemic circuit of the
double circulation is completed when the CO2 rich blood is carried back to the right
atrium of the heart via veins coming from the lower body and upper body [19–23].
1.3 Diseases of the Cardiovascular System
Cardiovascular diseases (CVDs) are mainly the diseases of the blood vessels, the heart,
and the vascular diseases of the brain. The different types of CVDs are summarized
below [1, 25].
CVDs caused by atherosclerosis:
• Ischaemic heart disease and coronary artery disease occur due to the disease and
blockage in the blood vessels supplying the heart muscle known as coronary arteries.
Acute coronary syndromes and heart attacks, also known as myocardial infarction
(MI), take place when the vessels supplying blood to the heart muscle are blocked
suddenly.
• Cerebrovascular diseases are caused by the disease of the carotid arteries; the blood
vessels supplying the brain. Strokes or transient ischemic attacks are the consequences
of the cerebrovascular disease.
• Peripheral artery disease, hypertensive heart disease, deep vein thrombosis and
pulmonary embolism are the main diseases regarding the circulatory system [1, 25].
Other CVDs:
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• Congenital heart disease
• Rheumatic heart disease
• Inflammatory heart disease
• Cardiomyopathies
• Heart failure
• Cardiac arrhythmias [1, 25].
According to the 2014 Global Status Report on Noncommunicable Diseases published
by World Health Organization (WHO), of the total 56 million deaths that took place
in 2012, 38 million were due to noncommunicable diseases such as CVDs, cancer,
chronic respiratory diseases and diabetes [2]. Based on WHO data, CVDs were the
number one cause of death in the world in 2012. In 2012, 17.5 million people died
from CVDs, making up 31% of all global deaths as demonstrated in Figure 1.3. 7.4
million of these deaths took place because of coronary heart disease, while 6.7 million
were due to stroke [25, 26].
In US, based on 2016 update of Heart Disease and Stroke Statistics that is brought
together by American Heart Association (AHA), Centers for Disease Control and
Prevention (CDC) and the National Institutes of Health (NIH), the overall rate of death
due to CVD was reported as 222.9 per 100.000 Americans in 2013. According to this
data, more than 2200 Americans die of CVD each day [27].
In Turkey, based on Turkish Statistical Institute Cause of Death Statistics of 2014 data,
the leading cause of death was cardiovascular diseases, represented with 40.4% of all
national deaths that took place in 2014. 39.6% of these CVD caused deaths occurred
due to ischaemic heart disease, followed by the cerebrovascular diseases, represented
by 24.7% of all CVD caused deaths [28].
Today, CVDs remain to be the leading cause of death in the world. The
main underlying pathological condition causing CVDs is atherosclerosis. While
atherosclerosis is an irreversible process beginning with birth, atherosclerotic CVDs
can be prevented if major risk factors are taken into consideration. Although some
major cardiovascular disease (CVD) risk factors that cannot be controlled exist, most
of the CVDs are caused by controllable, treatable or modifiable risk factors.
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Figure 1.3 : The global distribution of major causes of death in 2012 [25].
The major risk factors are the factors that have been demonstrated to significantly
increase the risk of CVDs. On the other hand, the so called "contributing risk factors"
have been associated with increased risk of CVD, but their significance in progression
of CVD is yet to be determined [29].
In 2011, AHA introduced a new concept of cardiovascular health, characterized by 7
metrics, named as Life’s Simple 7. These 7 metrics include health behaviors (having
a healthy diet, a sufficient physical activity, not-smoking, normal body weight) and
health factors (normal levels of blood cholesterol, blood pressure and blood glucose
in the absence of drug treatment). According to the concept, the ideal cardiovascular
health was defined by the presence of optimal levels of all 7 metrics together with the
absence of clinically manifested CVD [27].
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1.3.1 Cardiovascular disease risk factors
The major cardiovascular disease risk factors which cannot be changed are; increasing
age, male gender and heredity, while the treatable and modifiable ones include
smoking, high blood cholesterol, high blood pressure, physical inactivity, obesity and
diabetes mellitus.
The heart changes physiologically with increasing age, even without the presence of
any disease. When a CVD affects the heart, the changes in the heart due to old age
may further complicate the problem or its treatment. For example, after the age of 65,
the deaths attributable to coronary heart disease increase severely.
The risk of a heart attack is greater in men compared to pre-menopausal women. On
the other hand, the risk of stroke is similar for men and women.
In the case of heredity, a strong family history of cardiovascular disease poses great
risk, since children of parents with cardiovascular disease have more than one major
risk factor most of the time. The risk increases if a first-degree blood relative has
had a CVD before 55 years of age (for males) or 65 years of age (for females). In
addition, compared to Caucasians, African Americans are at greater risk due to their
higher blood pressure.
Smoking is one of the major modifiable risk factors for CVDs, especially when it is
together with other major risk factors. In coronary heart disease patients, smoking is
implicated in sudden cardiac death. AHA considers never having smoked or having
quit more than 12 months ago as one of the 7 components of ideal cardiovascular health
in adults [29, 30].
High blood cholesterol and abnormal levels of lipids in the blood constitute important
treatable and modifiable risk factors for cardiovascular disease. The risk of coronary
heart disease increases with high blood cholesterol levels. When present with other
risk factors such as high blood pressure and smoking, the risk increases even more.
Lipoproteins such as low-density lipoprotein (LDL) and high-density lipoprotein
(HDL) function in carrying cholesterol in blood. High levels of LDL cholesterol result
in rapid progression of atherosclerosis, therefore increase the risk of CVD. HDL carries
cholesterol away from the blood stream, thus higher levels of HDL are considered to
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reduce the risk of CVD. In addition to HDL and LDL cholesterol, blood triglyceride
levels are important. When combined with high levels of LDL cholesterol or low levels
of HDL cholesterol, higher levels of triglycerides in blood pose a risk of speeding up
the atherosclerotic process. The blood cholesterol levels are affected by age, gender,
heredity, diet and physical activity. Tables 1.1, 1.2 and 1.3 demonstrate the normal and
abnormal blood lipid levels [30, 31].
Table 1.1 : Total Cholesterol Levels [30, 31].
Total Cholesterol Level Category
Less than 200 mg/dL Desirable
200-239 mg/dL Borderline High
240 mg/dL and above High
Table 1.2 : LDL Cholesterol Levels [30, 31].
LDL Cholesterol Level Category
Less than 100 mg/dL Optimal
100-129 mg/dL Near Optimal Above Optimal
130-159 mg/dL Borderline High
160-189 mg/dL High
190 mg/dL and above Very High
Table 1.3 : HDL Cholesterol Levels [30, 31].
HDL Cholesterol Level Category
Less than 40 mg/dL Poor, major risk factor for CVD
40-59 mg/dL Better
60 mg/dL and higher Best, protective against CVD
High blood pressure, otherwise known as hypertension, is the systolic blood pressure
(maximum pressure in the arteries as the heart contracts) at or above 140 mmHg and/or
the diastolic blood pressure (minimum pressure in the arteries between the contractions
of the heart) at or above 90 mmHg. Hypertension leads to stress in blood vessels,
causing them to become weaker. Atherosclerotic plaques are mostly observed in
vulnerable locations such as arterial branching points where the blood flow is high
or disturbed. As the leading cause of CVD, hypertension is a major risk for coronary
heart disease and the single most important risk factor for stroke.
Along with physical inactivity, being overweight and obese constitute a major risk
factor for CVD progression. Body Mass Index (BMI) is an estimate of the body fat and
is used as a tool to screen for obesity and overweight. BMI is calculated by dividing
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the weight in kilograms to the square of height in meters. Table 1.4 shows the BMI
values and their corresponding explanations [32, 33].
Table 1.4 : Body Mass Index values [32, 33].
BMI Category
18.5- 24.9 Normal Weight
25- 29.9 Overweight
30- 39.9 Obese
40 and above Exteme Obesity
Diet and nutrition, alcohol consumption and stress are considered as the other risk
factors that contribute to progression of CVDs [30]. In addition to all the mentioned
CVD risk factors, some new ones that have been introduced lately include; elevated
levels of homocysteine, lipoprotein(a), c-reactive protein and fibrinogen [34].
1.3.2 Carotid artery disease
Figure 1.4 : The proximal aorta and carotid arteries [35].
As shown in Figure 1.4, some important branches of the proximal aorta include
the coronary arteries, the brachiocephalic artery that further branches into the right
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common carotid artery and right subclavian artery, as well as the left common carotid
and the left subclavian arteries. The coronary arteries supply blood to the heart
muscle, while the left and right subclavian arteries feed the left and the right arms
with blood [35].
The two carotid arteries, one located on each side of the neck, deliver blood to the brain.
The medical condition known as carotid artery disease is caused by the decreased
blood flow to the brain due to a blockage in the carotid artery. The sudden cease
of blood flow to a certain area in the brain causes stroke. Atrial fibrillation and
blockage in the carotid arteries are the two main causes of stroke. Unfortunately,
until the blockage in carotid artery causes the blood flow to brain to stop, there is
no way to understand the presence of it. When a brain area is deprived of blood
supply due to a blockage, its functions stop, causing symptoms of a stroke or a
transient ischaemic attack (TIA), such as painless loss of vision (Amaurosis fugax),
slurry speech, difficulty to speak, weakness in limbs and facial numbness. Carotid
artery disease is diagnosed with ultrasound of the carotid arteries as well as magnetic
resonance angiogram and computed tomography angiogram. These tests provide
information about the presence and the severity of a narrowing (stenosis) in the carotid
arteries [36]. It is of great importance to differentiate between symptomatic carotid
artery disease and asymptomatic disease. Asymptomatic severe carotid stenosis is
50–60% narrowing of the proximal internal carotid artery without the presence of
stroke or TIA symptoms [37].
To prevent the progression of disease, non-invasive therapies such as treatment of risk
factors such as hypertension, diabetes and high cholesterol are applied. For high grade
stenosis (≥ 60%), invasive therapies such as carotid endarterectomy and carotid artery
stenting are preferred. Carotid endarterectomy is an operation in which atherosclerotic
plaques are surgically removed from the carotid arteries and is performed to prevent
future strokes in symptomatic patients, while carotid artery stenting alternative is
offered to patients who cannot undergo carotid endarterectomy [36–38].
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1.4 Atherosclerosis
Atherosclerosis is the chronic, immunoinflammatory, degenerative disease of the
medium- and large-size arteries. It is a complex disease which involves interactions
of multiple genetic and environmental factors [39]. Progress of atherosclerosis
changes the arterial wall and leads to the build up of atherosclerotic plaques inside
arteries. Atherosclerosis is the underlying cause of many CVD diseases, including
coronary artery disease, stroke and peripheral artery disease [40]. Starting with birth,
atherosclerotic process progresses slowly and shows no symptoms for many decades.
When atherosclerosis presents symptoms in later stages of life, its complications, such
as myocardial infarction and stroke, are the leading causes of death in the Western
world [41].
As shown by the epidemiological studies which have been conducted for more than 50
years, atherosclerosis is a multi-factorial disease, in which environmental factors are
interacting with genetic components. The factors that contribute to the development
of atherosclerosis, as shown in Table 1.5, can be categorized as environmental factors
and as factors with a genetic background [6].
Table 1.5 : Environmental and genetic factors that contribute to development of
atherosclerosis [6].
Factors with a genetic background Environmental factors
High levels of LDL/VLDL High-fat diet
Low levels of HDL Smoking
High levels of lipoprotein(a) Low antioxidant levels
Hypertension Physical inactivity
High levels of homocysteine Infectious agents
Family history of CVDs
Diabetes and obesity
Depression
Male gender
Metabolic syndrome
Systemic inflammation
LDL: Low density lipoprotein
VLDL: Very low density lipoprotein
HDL: High density lipoprotein
CVD: Cardiovascular disease
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1.4.1 Pathogenesis of atherosclerosis
The wall of a normal blood vessel has three layers, the tunica intima, tunica media
and tunica adventitia. The intima layer is made up of a monolayer of endothelial
cells, which reside on a basement membrane containing type IV collagen, laminin
and heparan sulphate proteoglycans. The intima and the media layers are separated
by internal elastic lamina made up of elastin. The focal intimal thickenings rich in
sulphated polysaccharide and hyaluronic acid are exclusive to humans and intimal
smooth muscle cells (SMCs) can be found in these areas. Below, vascular SMCs
embedded in an interstitial matrix form the tunica media layer. The adventitia layer
contains capillaries, loose connective tissue, fibroblasts and fat cells, as shown in
Figure 1.5 [42].
Figure 1.5 : The three compartments of an artery [42].
In the inflammatory process of atherosclerosis, the intima layer gets thicker with lipid
rich material (atheroma) and connective tissue (sclerosis) [43]. Today, it is generally
believed that a response to injury initiated by circulating factors causes atherosclerosis,
owing to the "Response to Injury" hypothesis developed and published by Russell Ross
and John A. Glomset in 1973. In this hypothesis, it is stated that, it is the injury to
the endothelium that initiates the pathogenesis of atherosclerosis [44]. In this model
of atherogenesis, potential sources of injury, such as hyperlipidemia, hypertension,
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metabolites, infections and mechanical factors such as shear stress were suggested
to cause the initiation of atherosclerosis. The aggregation of platelets, retention of
oxidized lipids and migration of smooth muscle cells to the intimal layer are the events
that were suggested to follow the initial injury to eventually cause plaque formation.
This hypothesis was supported by various results from studies with animal models [45].
Figure 1.6 : Stages of atherosclerosis [20].
As demonstrated in Figure 1.6, the development of atheromatous plaques inside the
arteries is referred to as atherogenesis, which takes place in distinct stages:
•The normal vessel wall,
•The first lesions; fatty streaks,
•Atherosclerotic plaques,
•Ruptured plaques with thrombosis [40].
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Atherosclerosis is characterized by vascular inflammation and the accumulation of
lipids, cholesterol, calcium, and cellular debris inside the intima of the vessel
wall. The pathological changes in atherosclerosis occur due to molecular events of
endothelial dysfunction, monocyte adherence and entry into the vessel wall, monocyte
development into foam cells, smooth muscle cell migration and proliferation, and
platelet adhesion and aggregation [39, 40].
1.4.1.1 Initiation of atherosclerotic lesions
The vascular wall homeostasis is regulated by the endothelium. The mediators
such as nitric oxide, prostacyclin and endothelin that are released by endothelial
cells function in controlling vascular tone and maintaining low levels of oxidative
stress. The endothelium regulates processes including vascular permeability, platelet
and leukocyte adhesion and aggregation, as well as thrombosis [46]. The healthy
endothelium changes to a non-adaptive state, in which the homeostatic mechanisms
of endothelial cells are dysregulated, in response to various stimuli such as diabetes,
dyslipidaemia, hypertension, shear stress related cell injury, smoking and most
importantly, oxidized low density lipoprotein (ox-LDL) [47]. This situation, which the
endothelium can no longer protect the vessel wall is named as endotelial dysfunction
[40, 46].
Fluid shear stress is one of the many physical forces that affect endothelial cells. For a
healthy vessel function, the physiologic, laminar shear stress needs to be maintained.
Shear stress affects the morphology of endothelial cells; where blood flow is uniform
and laminar, the cells, aligned in the direction of flow, are ellipsoid shaped. On the
other hand, in regions where there is disturbed blood flow, such as arterial branching
sites, endothelial cells are polygonal shaped and without a particular orientation. The
areas of disturbed flow are prone to lesion formation, because nonlaminar flow alters
the endothelial gene expression, cytoskeletal arrangement and leukocyte adhesion [48].
The cells in the these areas are more permeable to molecules such as LDL [6].
The first step in the formation of early lesions is endothelial dysfunction taking place
as a response to various triggers, such as ox-LDL [49]. The most important events that
take part in fatty streak formation are, the recruitment of monocytes, differentiation
of monocytes into macrophages and the uptake of LDL-derived cholesterol by these
16
Figure 1.7 : Role of shear stress in atherosclerosis progression [48].
macrophages. The oxidative modifications in LDL, especially in the lipid and
the apolipoprotein B components, cause endothelial dysfunction and initiation of
inflammatory response, thus contribute to fatty streak formation [50].
1.4.1.2 Foam cell formation
Inflammation runs in almost all stages of atherogenesis, starting with endothelial
dysfunction. Cell adhesion molecules expressed by endothelial cells, including
Vascular Cell Adhesion Molecule-1 (VCAM-1), E selectin and P selectin, and
Intercellular Adhesion Molecule-1 (ICAM-1), are upregulated in response to these
stimuli that cause endothelial dysfunction. As a result, monocytes and T cells in
circulation are recruited to the areas which are prone to atherosclerosis [14, 51].
Together with cell adhesion molecules, ox-LDL serves as a chemoattractant molecule
too for monocytes. In addition, the expression of chemotactic molecules, such as
monocyte chemotactic protein-1 (MCP-1), is triggered by ox-LDL [52].
After monocytes are attracted to the arterial wall in response to chemotactic signals,
they move to the subendothelial region and differentiate into macrophages within the
intimal layer and internalize ox-LDL via their scavenger receptors. This protective
function of monocytes to remove the ox-LDL particles or apoptotic cells ends up with
the uptake of ox-LDL molecules by macrophages, causing foam cell formation. The
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presence of foam cells in the intima is a hallmark of the earliest atherosclerotic lesions,
fatty streaks [14, 49, 51].
Figure 1.8 : Foam cell formation [51].
According to the "Oxidative modification hypothesis of atherosclerosis", for the rapid
uptake of LDL by macrophages, it needs to be highly oxidized. The uptake results in
foam-cell formation. This process is mediated by scavenger receptors (SRs). Certain
scavenger receptors, such as SRA, SRB and Lectin-like ox-LDL receptor-1 (LOX-1)
have been implicated in atherogenesis due to their role in receptor mediated uptake of
modified LDL [49, 53].
1.4.1.3 Fibrous plaques
The initial lesions of atherosclerosis, the fatty streaks can be observed in the aorta
in the first decade of life, while they emerge in the coronary arteries in the second
decade, and the cerebral arteries in the third or fourth decades in humans. Though
fatty streaks do not have clinical significance, their importance as precursors of more
advanced lesions have been recognized. The characteristics of these more advanced
lesions, named as fibrous plaques, are the accumulation of smooth muscle cells and
necrotic debris rich in lipids [6].
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Figure 1.9 : Progression of atherosclerotic lesions [47].
As the disease progresses, a transition from simple fatty streak to a complex lesion
takes place. The smooth muscle cells migrate from the tunica media layer, passing
the internal elastic lamina, into the tunica intima. They proliferate in intima in
response to mediators such as platelet derived growth factor. The intimal smooth
muscle cells further contribute to the formation of foam cells by taking up modified
lipoproteins [43, 54]. As the SMCs in intima start producing extracellular matrix
molecules, such as interstitial collagen and elastin, the emergence of the fibrous cap
is observed. Apoptosis of the foam cells result in extracellular lipid accumulation,
creating the necrotic core within the plaque [14, 55].
1.4.1.4 Advanced plaques, neoangiogenesis and thrombosis
The arterial lumen narrows with the progressing lesion, resulting with a decrease in
the blood flow and eventually tissue ischemia. Finally, the ischemia is precipitated
as the plaque is physical disrupted. The characteristics of plaques that are prone
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to rupture (vulnerable plaques) include a large lipid-rich core, a thin fibrous cap
with fewer smooth muscle cells and many macrophages, angiogenesis and adventitial
inflammation. Devastating consequences of the plaque rupture are myocardial
infarction and stroke [14, 49].
In carotid artery disease, strokes mostly take place due to thrombosis resulting from the
rupture of atherosclerotic plaques [56]. Thrombus formation is known to be associated
with plaque instability, instead of plaque size [57]. Angiogenesis inside the plaques has
been associated with qrowth of the plaques, its rupture, intraplaque hemorrhaging and
thrombosis [58,59]. It is not clear at which stages of plaque formation neoangiogenesis
occurs, although new vessel formation has been reported in fatty streaks and was found
to increase with the progressing lesions [60].
In studies performed with apolipoprotein E knock-out mice, lesion growth was
suppressed when neoangiogenesis was inhibited, suggesting the contribution of
neoangiogenesis to plaque vulnerability in atherosclerosis [61].
1.4.2 Genetic susceptibility to atherosclerosis
The molecular mechanisms leading to atherosclerosis are partially understood.
Multiple risk factors have been identified by large-scale epidemiological studies
performed in families with premature cardiovascular disease and in monozygotic and
dizygotic twins. There is a significant genetic component behind each of the traditional
risk factors, such as dyslipidemia, obesity, diabetes mellitus, and hypertension. On
the other hand, population migration studies emphasize the impacts of environmental
factors. Thus, the overall risk of atherosclerosis is determined by the interaction of
genetic and environmental factors [41, 62, 63].
In most premature forms of atherosclerosis, there is involvement of increased plasma
levels of pro-atherogenic lipoproteins. Almost 50% of the total variance in plasma total
cholesterol, HDL cholesterol and triglycerides levels have a genetic background. The
plasma levels of lipoproteins are determined by multiple genes, except for a few rare
Mendelian forms. For this reason, single nucleotide polymorphisms (SNPs) in genes
involved in lipid and lipoprotein metabolism are considered as primary candidates for
susceptibility genes to atherosclerosis [64].
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While atherosclerosis is a complex (polygenic) disease, single-gene forms of
atherosclerosis exist as well. These Mendelian forms of the disease have provided
valuable bases for elucidating the factors contributing to atherosclerosis. Of the many
monogenic diseases that elevate plasma levels of LDL, familial hypercholesterolemia
(FH) was the first to be discovered. In FH, LDL plasma levels are elevated because the
hepatic LDL receptors, which normally function in clearing LDL from the plasma, are
impaired. More than 600 mutations have been identified in the Ldlr gene of patients
with FH. Severe coronary atherosclerosis is observed in patients with homozygous FH.
These patients suffer from myocardial infarction and die in childhood [39, 65].
Similar to Ldlr, Apolipoprotein B (Apob) and Apolipoprotein E (Apoe) genes are
higly polymorphic. Mutations in the Apob gene result in reduced binding of
apolipoprotein B-100 to LDL receptors, elevating plasma LDL cholesterol levels
and causing familial ligand-defective apolipoprotein B-100 disorder (FDB). Familial
hypobetalipoproteinemia (FHBL) is the other genetic disorder caused by mutations
in Apob gene [66, 67]. However, the most crucial protein in the lipid transport
system is Apolipoprotein E (APOE), which takes part in formation of HDL particles
as well as modulating serum cholesterol levels. Apoe gene has three major alleles
(Apoe2-4). The wild-type protein is encoded by E3 allele, while E2 is implicated with
type III hyperlipoproteinemia and allele E4 has been demonstrated to contribute to
athorosclerosis pathogenesis [68–71]. In addition, ATP binding cassette transporter
1 (Abca1) gene mutations cause Tangier disease, which is characterized by severe
HDL deficiency and premature atherosclerosis. Similar to genes and loci implicated
in dyslipidemia, many candidate genes have been identified for the other risk factors,
especially for Mendelian forms of high and low blood pressure [41, 72, 73].
However, in the case of atherosclerosis, multiple genes take part in disease
pathogenesis. Up to date, candidate gene studies and genome-wide linkage studies
to find atherogenesis-regulating quantitative trait loci have been useful tools in
elucidating the genetic basis of atherosclerosis. Via whole genome sequencing,
genome-wide association studies (GWAS) to identify responsible genes could be
conducted. The largest GWAS for coronary artery disease was the CARDIoGRAM
study that included more than 100,000 subjects of European descent. Together with
smaller studies of Asian populations, nearly 30 loci were identified [74, 75]. Some of
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the genes that have been found to be atherosclerosis-related by candidate gene studies,
linkage analysis and association studies are given in Table 1.6 [3].
Table 1.6 : Genetic studies related to Cardiovascular Diseases [3, 76–83].
Defective gene Related Syndrome
(1),(2)5-lipoxygenase Atherosclerosis
(2)Phosphodiesterase 4D Stroke, atherosclerosis
(3)Lymphotoxinα Myocardial infarction
(3)Connexin 37 Myocardial infarction
(3)Plasminogen activator inhibitor 1 Myocardial infarction
(3)Stromelysin Myocardial infarction
(2)Myocyte enhancer factor 2 Myocardial infarction
(2)Linkage chromosome 14 Myocardial infarction
(1)Toll-like receptor 4 Atherosclerosis
(1)Candidate gene studies
(2)Linkage analysis
(3)Association studies
For identifying the polymorphisms in genes for risk factors of atherosclerosis, such
as hypertension and diabetes, large-scale sequencing studies are being performed.
The fact that whole genome sequencing studies for diabetes, dyslipidemia, and
hypertension associated loci have yielded only limited number of loci points out to
the complex nature of all these traits [6].
For investigating the genes that take role in atherosclerosis, animal models, especially
mice and rats, are used widely [51]. Most of the animal models are used in studies
concerning lipid metabolism. Wild-type mice are resistant to atherosclerosis, mainly
because cholesterol circulates in high density lipoprotein particles, as opposed to
humans, which have circulating cholesterol in low density lipoprotein. To overcome
this barrier, many genetically modified mouse models have been generated [84]. One
well known example is the apolipoprotein E-knockout (apoE-KO) mice, in which the
apolipoprotein (apo) E gene has been deleted. These mice develop atherosclerosis
spontaneously due to hypercholesterolemia, therefore represent a powerful tool for
modeling and prevention of the disease [85].
Some other mouse models used for lipid metabolism studies include, LDL receptor
deficient KO mice [86], Apo E3-Leiden transgenic mice [87] and Hepatic lipase-KO
mice [88]. Similar to LDL receptor deficient KO mice, Watanabe Heritable
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Hyperlipidemic (WHHL) rabbits naturally lack LDL receptors and thus are used in
these studies [89].
1.5 Atherosclerosis and Angiogenesis
All of the cells of a human body need a well-controlled supply of oxygen. Since
oxygen diffusion in tissues is limited with 100 to 200 µm, our highly developed
vascular system has evolved to meet the need of this close proximity to an oxygen
supply. Every metabolically active tissue in the body is only a few hundred
micrometers from a blood capillary that is in charge of exchanging nutrients and
metabolites with its surroundings. This well-developed system is maintained by
angiogenesis; the process of new vessel formation from existing ones [90, 91].
In the embryonic stage, the first organ system to develop is the cardiovascular
system [92]. In the circulatory system, the single layer of endothelial cells coating
the luminal surface of vessels originate from mesoderm. Mesodermal stem cells
give rise to hemangioblasts which differentiate into hematopoietic stem cells and
angioblasts. In the embryonic stage, blood vessels are formed by the process of
vasculogenesis via differentiation of angioblasts that come together to form primitive
vessels. Vasculogenesis is directed by growth factors and morphogenes. Cell-cell
and cell-extracellular matrix interactions are needed for this dynamic process [93,
94]. When new vessels start to grow during vasculogenesis, a switch is triggered
in endothelial cells that enable them to change from their quiescent state into a
proliferating, migrating state. This is accomplished by hypoxic conditions (insufficient
oxygen concentration) that usually occur during tissue expansion. In such conditions,
angiogenesis is engaged by a genetic regulatory master switch that is activated via the
oxygen sensing transcriptional system. Angiogenesis continues throughout the adult
life, occurring in both health and disease [95].
Any blood vessel of the body is made up of two different cell types: endothelial cells
(ECs) and mural cells. In the capillaries, only the ECs make up the vascular wall,
whereas in larger vessels such as the arteries, the vascular wall consists of many layers
as demonstrated in Figure 1.10. The inner layer, termed as tunica intima, is formed
exclusively by the ECs. The elastic connective tissue of the middle layer, named as
the tunica media, consists of mural cells, particularly the smooth muscle cells. Tunica
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Figure 1.10 : Structure of an artery [96].
adventitia, the outer layer, is made of connective tissue mainly. While endothelial
cells form the inner vessel wall, the mural cells, such as vascular smooth muscle cells
and pericytes, take part in coating the endothelial cell tube. Vascular smooth muscle
cells form multiple layers around arteries and veins, while pericytes interact with the
smaller diameter blood vessels such as arterioles and capillaries, sharing their basal
membrane with the endothelium. Endothelial cells are the most important type of
vascular cells that take part in angiogenesis. The two main types of angiogenesis taking
place in tissues include sprouting angiogenesis and intussusceptive angiogenesis as
demonstrated in Figure 1.11 [95, 97].
As the name implies, the characteristic structures of sprouting angiogenesis are
sprouts made up of endothelial cells growing toward angiogenic stimuli. Sprouting
angiogenesis is capable of adding blood vessels to parts of tissues where there were no
blood vessels before. However, in the case of intussusceptive angiogenesis, elements
of interstitial tissues invade existing vessels and form transvascular tissue pillars that
expand [91].
Sprouting angiogenesis usually begins in poorly perfused tissues. Parenchymal cells
such as myocytes, hepatocytes, neurons and astrocytes secrete a proangiogenic growth
24
Figure 1.11 : Formation of blood vessels [98].
factor called vascular endothelial growth factor (VEGF-A) to respond to the hypoxic
environment. As a result, a vessel sprout is directed through the extracellular matrix
(ECM) towards the VEGF-A by an endothelial tip cell [99–101]. The capillary sprout
is elongated by the proliferation of endothelial stalk cells that follow the tip cell. A
lumen is formed within a series of stalk cells as vacuoles develop and fuse inside them.
When more than two tip cells of capillary sprouts converge at the VEGF-A source,
they fuse together to form a continuous lumen through which oxygenated blood flows.
VEGF-A levels return to near normal as the local tissues are oxygenated [91,102,103].
1.6 Signalling Pathways In Angiogenesis
Angiogenesis is tightly controlled by a system that employs both the pro-angiogenic
and anti-angiogenic factors. The angiogenic process is physiologically balanced
between the stimulatory and inhibitory signals. In adults, angiogenesis takes place
during wound healing, organ regeneration, ovulation, menstruation, and during the
formation of the placenta in females. The dysregulation of angiogenesis has been
linked to several pathological processes such as tumor growth, rheumatoid arthritis,
diabetic retinopathy, and psoriasis. For example, aberrant angiogenesis has been
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shown to promote cancer and neovascular age-related macular degeneration, while
ischemic diseases of the heart, brain and limbs are known to be caused by insufficient
angiogenesis [90, 104].
The role of angiogenesis in atherosclerosis has been the subject of debate and remains
as an unresolved issue, therefore research on elucidating the role of angiogenesis and
signalling pathways taking part in angiogenesis is required.
1.6.1 Vascular endothelial growth factor (VEGF) pathway
Vascular endothelial growth factor (VEGF) signaling pathway is very important
for regulating sprouting angiogenesis in physiological and pathological conditions.
Endothelial differentiation, migration, proliferation, survival, and permeability are
controlled via this signalling pathway. The superfamily of vascular endothelial growth
factor (VEGF) includes VEGF ligands, receptors and the molecules that interact with
them. The VEGF ligands and receptors are attractive targets for therapeutic approaches
since excessive or insufficient angiogenesis is the crucial element in many diseases.
Therefore, understanding the mechanism of action of this family of ligands that act
through three receptor tyrosine kinases (RTKs) is important.
VEGFs are members of Vascular endothelial growth factor (VEGF) / Platelet-derived
growth factor (PDGF) group of the cystine-knot superfamily of hormones and
extracellular signaling molecules. All of the members of this superfamily contain
a VEGH homology domain that is made up of eight conserved cysteine residues
forming the typical cystine-knot structure. All VEGF family members modulate their
abilities of binding to VEGF receptors as well as co-receptors such as neuropilins
by increasing their complexity via alternative splicing and processing [90, 105, 106].
The vascular endothelial growth factor family has six secreted dimeric glycoprotein
members in mammals; VEGF-A (VEGF), VEGF-B, VEGF-C, VEGF-D, VEGF-E and
placental growth factor (PlGF). All of these members of the VEGF family bind to the
three VEGF tyrosine kinase receptors (VEGFR1, VEGFR2, VEGFR3) with different
affinities [107].
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1.6.1.1 VEGFR2 signalling
Just like many other signalling proteins, VEGF family members act through by binding
to receptor tyrosine kinases for achieving their biological functions. Upon ligand
binding, the receptor chains of RTKs dimerize, causing the kinase domains of the two
receptor chains to be brought together. When they are in close proximity, they become
activated and phosphorylate each other on multiple tyrosine residues in a process
known as trans-autophosphorylation. The phosphorylation of tyrosine residues in
the kinase domain inreases the kinase activity, while the phosphorylation of tyrosines
outside the kinase domain result in docking sites for intracellular signalling proteins to
bind. Some of the important intracellular signalling proteins that function in relaying
the signal forward include phospholipase C-γ (PLC-γ) and phosphoinositide 3-kinase
(PI3K). These intracellular signalling proteins are able to bind to phosphotyrosines
due to their highly conserved phosphotyrosine-binding domains such as Src homology
region (SH2) or Phosphotyrosine-binding (PTB) [108].
VEGF family members bind to three VEGF receptors; (VEGFR)-1, VEGFR-2, and
VEGFR-3. VEGFR1 that binds to VEGF, VEGF-B, and PlGF plays a role in
vasculogenesis, and is suggested to facilitate hematopoiesis and recruit endothelial
cell progenitors to tumor blood vessels from bone marrow. It has not been completely
elucidated through which mechanisms VEGFR1 functions. In addition, the role of
VEGFR1 in adult angiogenesis is not well-known [109].
VEGF-C and -D bind to VEGFR3, which is associated to formation of the lymphatic
vessels and tumor development. The importance of VEGFR3 mediated activation of
lymphatic endothelial cells in tumor metastasis has been demonstrated. Along with the
three VEGF receptors, the co-receptors Neuropilin-1 (Nrp-1) and Neuropilin-2 (Nrp-2)
bind to the heparin binding isoforms of VEGF and enhance the binding of VEGF to
VEGFR1, and VEGFR2 [111].
VEGFR2 is the main receptor that plays a role in VEGF-driven angiogenesis.
VEGF binding to VEGFR2 results in activation of downstream effector molecules
such as PLC-γ , protein kinase C, Rat Sarcoma (RAS), Rapidly Accelerated
Fibrosarcoma (RAF), the Mitogen Activated Protein Kinase (MAPK)/ Extracellular
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Figure 1.12 : VEGFR2 signalling [110].
Signal-Regulated Kinase (ERK) signaling cascades, the PI3K and Focal Adhesion
Kinase (FAK) pathways. As is demonstrated in Figure 1.12, activation of MAPK,
PI3K/Protein Kinase B (AKT) signalling pathways lead to angiogenesis, endothelial
cell proliferation, migration, and survival [112–115].
1.6.1.2 VEGF pathway’s negative regulators
Angiogenesis depends on the ability of endothelial cells to correctly process the
signals from growth factors that bind to their RTKs on the cell surface, activating
many intracellular signaling pathways whose outputs are cell growth, migration,
and morphogenesis. Endothelial cells can modulate their response to these growth
factors by also inhibiting the downstream signalling cascades. Elucidating the control
mechanisms and regulators of these signalling cascades is crucial to understanding
physiological and pathological angiogenesis.
Sprouty family of proteins include Sprouty proteins and Sprouty-related proteins, both
of which take part in organogenesis, especially during the branching of endothelial
tubes. They are highly conserved modulators of MAPK/ERK pathway and negatively
regulate growth factor signaling [116, 117]. A member of the family, Sprouty-related
Ena/VASP homology 1 (EVH1) domain-containing protein 1 (SPRED1), encoded by
Spred1 gene, works as homodimer or as a heterodimer together with SPRED2 and
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regulates the activation of the MAP kinase signalling [118]. It was discovered that
in response to growth factors, SPRED1 was phosphorylated and that through the
formation of RAS-SPRED1 complex, it suppressed the phosphorylation, therefore
activation of RAF1, an upstream kinase of the MAPK/ERK pathway. Via this
mechanism, SPRED1 inhibits MAP kinase activation and represses the VEGF
signalling [119].
Phosphoinositide 3-kinase (PI3K) family members are heterodimeric lipid kinase
enzymes, with their distinct regulatory (p85) and catalytic (p110) subunits
encoded by different genes. They take part in phosphorylating the D3
hydroxyl group of membrane phosphatidylinositols when stimulated by recep-
tor tyrosine kinase and G-protein-coupled receptor or upon RAS activation.
PI3K converts the plasma membrane lipid phosphatidylinositol-4,5-bisphosphate
(PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3), which binds to the
pleckstrin-homology (PH) domains of AKT and phosphoinositide-dependent kinase
1 (PDK1). When in close proximity, PDK1 phosphorylates AKT, causing
phosphorylation of many proteins affecting cell growth and survival. Just like
MAPK/ERK, PI3K/AKT is a crucial signalling cascade for cell fate [120–122]. PI3K
regulatory subunit p85 is made up of the α and β proteins [123]. Similar to SPRED1,
phosphoinositol-3 kinase regulatory subunit 2 (PIK3R2 or p85 β ) functions as a
negative regulator of VEGF signalling by inhibiting PI3K cascade [124].
1.6.2 Notch signalling and angiogenesis
Along with VEGFR2 signaling, there are many other factors that take part in regulation
of angiogenesis. Notch signalling, an evolutionarily conserved pathway with crucial
roles in the determination of cell fate in all metazoans, is needed for normal embryonic
development, the regulation of tissue homeostasis, and adult stem cell maintenance.
There are four Notch receptors (Notch 1–4) and five ligands (Delta-like-1, -3, -4 and
Jagged-1 -2) in mammals. Both the receptors and the ligands are located on the
cell surface. Notch receptors are synthesized as single-chain precursors and cleaved
into extracellular and transmembrane subunits in the Golgi apparatus. Held together
on cell membrane by non-covalent bonds, these subunits are activated when they
interact with ligands present on the cell membrane of neighbouring cells. A series
29
of proteolytic cleavages of Notch take place upon ligand binding, starting with the
removal of extracellular subunit by a disintegrin and metalloprotease (ADAM) and
followed by an intramembranous cleavage by γ-secretase. Via cleavage by γ-secretase,
active form of Notch (NIC) is released, which then translocates into the nucleus to
modulate transcription [125, 126].
The role of Notch signaling in sprouting angiogenesis is to determine which cells
should become tip and which should become stalk cells. Upon VEGFA stimulation,
Notch ligand Delta-like 4 (Dlt4) is upregulated, causing binding of DLL4 to the Notch1
receptors on the neighboring endothelial cells. Notch1 receptor activation causes
downregulation of VEGFR2 and as a consequence, VEGFR2 signaling is inhibited
in these cells. Activation of Notch during vascular injury suggests that this pathway
plays important role in limiting damages to the vascular structure. Via regulating the
number of sprouts, DLT4/NOTCH1-mediated signaling modulates VEGF-A-driven
angiogenesis [125, 127].
1.7 The contribution of angiogenic signalling pathways to pathogenesis of
atherosclerosis
The argument that intraplaque neoangiogenesis contributes to atherosclerotic lesion
development is supported by the fact that once the thickness of the vessel wall
exceeds a critical depth due to neointimal growth, the supply of oxygen and other
nutrients to the media and neointima will be resticted. When the interior of the
artery becomes hypoxic, hypoxia-inducible transcription factors (HIFs) that induce
expression of VEGF and other angiogenic regulators are stimulated. The stimulation
of VEGF results in angiogenesis, promoting plaque growth. Evidence demonstrating
the presence of VEGF-A in human atherosclerotic lesions showed a rise in VEGF-A
during disease progression. VEGFR2 signalling pathway is implicated in triggering
neoangiogenesis in the intima, thereby in promoting lesion progression [16, 127].
Notch is crucial for cardiovascular system development and maintenance, under
normal and pathological conditions such as ischaemia, neoangiogenesis. How Notch
contributes to molecular mechanisms underlying atherosclerosis is not yet elucidated.
Atherosclerotic lesions occur in arterial branch points, where there is disturbed
blood flow and low shear stress which cause endothelial dysfunction, a hallmark
30
of atherosclerosis progression. Studies focused on modulation of Notch signalling
by shear stress have demonstrated a decrease in expression of Notch signalling
components in atheroprone regions of mouse aortic arch. These results suggest that in
areas with disturbed blood flow, Notch signalling is affected, therefore there areas are
predisposed to atherosclerosis. The extent of angiogenesis and the number of sprouting
is determined by a balance between the Notch signalling and growth factors [128].
New blood vessel formation in atherosclerotic plaques is puzzling and no consensus
has been reached on whether angiogenesis either contributes to the pathogenesis of
atherosclerosis or is a treatment approach in CVDs [15]. Despite the fact that an
association between intraplaque angiogenesis and atherosclerosis progression exists,
the use of VEGF to stimulate blood vessel formation in an approach called therapeutic
angiogenesis has been a valuable tool for the treatment of ischemic heart and limb. On
the other hand, to stabilize the plaques and to avoid intraplaque hemorrage, eliminating
neoangiogenesis within atherosclerotic lesions via molecular therapies is proposed
[16, 17].
1.8 MicroRNAs
When the nematode Caenorhabditis elegans (C.elegans) lin-4 gene that controls the
timing of larval development was demonstrated to be a non-coding gene, microRNA
genes were discovered for the first time as genes that produce a pair of small RNAs
[129]. Following the discovery of lin-4 RNA, the 22 nucleotide long let-7 RNA
encoded by let-7 gene was demonstrated as a small RNA that plays a role in larval
development of C.elegans [130]. Since then, a vast number of genes encoding these
small temporal RNAs were revealed in worm, fish, fly and mammalian genomes. The
small RNA lin-4 is accepted as the founding member of these small RNAs now called
microRNAs [131, 132].
MicroRNAs, miRNAs in short, are small, single-stranded RNA molecules. They are
usually 18 to 22 nucleotides in length and they are non-coding RNAs with regulatory
functions. They take roles in many important biological functions and cellular events.
Some of the crucial cellular processes that miRNAs take part in regulation include,
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cell proliferation, metabolism, apoptosis, senescence, tumorigenesis, angiogenesis,
differentiation and development [40].
1.8.1 MicroRNA biogenesis
Almost a quarter of the genes encoding miRNAs are located in the introns of
pre-mRNAs and are co-expressed with their host genes, while some of them
are clustered in the genome. MicroRNA expression is known to be specific to
developmental stages and it is also tissue-specific. In Homo sapiens, nematodes
and Drosophila, miRNAs are thought to account for nearly 1% of all genes and
conservation of miRNA genes is observed among closely related species.
In Eukaryotes, miRNAs biogenesis begins when RNA polymerase II transcribes a
primary product that is several thousand nucleotides long which contains stem–loop
structures (pri-miRNA). Following transcription, cleavage of this pri-miRNA occurs
in nucleus and pre-miRNA with a small hairpin structure is liberated. This step is
performed by the nuclear RNAse III-endonuclease Drosha.
After its cleavage in nucleus, pre-miRNA is transported to the cytoplasm via a
nucleo/cytoplasmic cargo transporter, Exportin-5, as demonstrated in Figure 1.13.
Another RNAse III-endonuclease located in cytosol, Dicer, cleaves the pre-miRNA
hairpin structure into a small double-stranded RNA duplex that is made of a mature
RNA stand and its complementary strand. These two strands are also termed as miR-5p
and miR-3p [133, 134].
Upon cleavage, the double stranded duplex generated by Dicer is loaded into an AGO
protein and RNA-induced silencing complex (RISC) is formed. AGO proteins are part
of the Argaunate family proteins. As the integral parts of the RISC complex, they
bind to small non-coding RNAs and play role in RNA silencing as effector molecules.
When the AGO protein associates with RNA duplex, the pre-RISC complex is formed.
In pre-RISC, the complementary strand of the duplex is degraded and mature RISC is
generated. [135].
The RISC complex chooses the RNA strand with the lowest thermodynamic stability
at its 5’ end as the guide strand, while the complementary strand is often degraded.
The guide strand leads RISC to its target [40, 136].
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Figure 1.13 : MicroRNA biogenesis [40].
1.8.2 Regulation of gene expression by microRNAs
RNA interference is gene-silencing at the post-transcriptional level by small RNAs,
such as microRNAs, small interfering RNAs (siRNA) and short hairpin RNAs
(shRNA). When a miRNA is incorporated in RISC complex, it binds to the 3’
untranslated (UTR) region of the targeted messenger RNA (mRNA) to accomplish
gene silencing via different mechanisms. The mRNA target recognition is mediated via
a complementation between the 2nd–8th nucleotides of the miRNA, known as the seed
sequence, and the target mRNA [137, 138]. Gene silencing by microRNAs through
RISC is accomplished in two main ways: mRNA decay and translational repression as
demonstrated in Figure 1.14 [139–141].
Nearly %50 of human transcriptome is known to be under regulation of miRNAs.
Many crucial cellular processes in which miRNAs exert their regulatory function have
been elucidated in the last ten years. MiRNAs have been linked to several pathological
conditions, some of which include, cancer, cardiovascular disorders, neurological
pathologies, autoimmune diseases, metabolic diseases, obesity, hepatological disorders
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Figure 1.14 : Mechanism of gene silencing by miRNAs [139].
and viral diseases. For these reasons, investigating and elucidating the roles of
miRNAs in the regulation of such conditions is one of the rising topics of research.
Researchers working with miRNAs make use of online resources and algorithms
identifying miRNAs, predicting their targets and investigating their functions. Of these
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databases, servers and algorithms, MiRBase, TargetScan, PicTar and Miranda are the
most widely used ones [142–146].
1.8.3 MicroRNAs in cardiovascular diseases and angiogenesis
MicroRNAs are important regulators of biological processes. They are linked to
atherosclerosis, angiogenesis and many cardiovascular pathological conditions, such
as ischaemic heart disease, hypertension and arrhythmias [18, 147]. They have been
suggested to regulate atherosclerotic process by taking part in its stages, including
endothelium dysfunction, cellular adhesion, plaque development, and plaque rupture
[147, 148].
Dicer and Drosha deletion studies have provided insights to the role of miRNAs in
angiogenesis and endothelial function. The microRNAs that take part in regulation
of angiogenesis are named as angiomiRs. Defects in vascular remodeling during
development have been observed in Dicer hypomorphic mouse lines. Similary, the
result of knockdown of Dicer or Drosha in human endothelial cells was found to
decrease angiogenesis [149].
Extracellular signals, such as growth factors or hypoxia, turn the related signal
transduction pathways on and in return, specific effectors such as, mitogen-activated
protein kinase, or Akt are activated or gene expression is induced, resulting in an
angiogenic response. MiRNA biogenesis, expression or degradation can be modulated
through the the activation of the signal transduction pathways. Figure 1.15 shows the
effect of stimuli such as VEGF, hypoxia, or mitogens on promoting angiogenesis and
participation of miRNAs in these processes [150].
MiRNA expression is known to be specific to tissues and different cell types. Studies
aiming to profile miRNA expression patterns in endothelial cells have demonstrated
that miRNAs, including let-7b, miR-16, miR-21, miR-23a, miR-29, miR-100,
miR-221, miR-222 and miR 126 are expressed in endothelial cells [147]. Some of
the miRNAs that are known to play roles in angiogenesis include, let-7f, miR-17∼92
cluster, miR-126, miR-21, miR-27b, miR-31, miR-210, miR-221/222, miR-296 and
miR-378. However, the only miRNA that was found to be expressed exclusively both
in endothelial cells and endothelial progenitor cells is miRNA-126 [149].
35
Figure 1.15 : Regulation of angiogenesis via miRNAs [150].
Several miRNAs have been implicated in the regulation of cellular processes in
atherosclerosis. To date, the miR 126, miR 145 and miR 155 triad have been
studied. MiR-145 was found to be down-regulated in smooth muscle cells. This
down-regulation was suggested to contribute to atherosclerotic lesion formation. On
the other hand, in macrophages, the high expression levels of miR-155 had a relieving
effect on advanced atherosclerosis [151].
1.8.4 MicroRNAs 126-3p, -5p and their host gene Egfl7
MiR 126-3p and miR 126-5p are a set of crucial miRNAs for endothelial cells.
Both of them are conserved among species and they originate from the precursor
molecule pre-miR-126. Unlike many miRNAs, passenger strand of miR 126-3p, miR
126-5p (also shown as miR-126*) is not degraded [152]. Both of the MiRNAs are
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encoded by the miR-126 gene, which resides within the intron of Egfl7 gene located at
chromosome 9q34.3 [153].
MiR-126 is up-regulated in embryonic stem cell- derived endothelial progenitor cells
during embriyonic developmental stages. In the embriyogenic stage, for generation of
initial vascular plexus, VEGF is needed, and VEGF-driven angiogenesis is modulated
by miR-126. The VEGF signaling suppressor molecules, Sprouty-related protein
SPRED1 and phosphoinositol-3 kinase regulatory subunit 2 (PIK3R2) are targeted by
miR-126 [154]. The inhibition of Pik3r2 results in an up-regulation in angiopoietin-1,
which functions as a proangiogenic signalling factor with a role in stabilizing and
maturation processes of the vessels, which is normally down-regulated by PI3K/Akt
signaling [155].
MiR 126-3p is highly expressed in vascularized tissues such as heart, liver and
lungs. Expression studies demonstrated its specific expression in the endothelial
cell lineage, hematopoietic progenitor cells,and endothelial cell lines [152]. Deletion
of MiR-126 in mice (without altering Egfl7 expression) results in major defects in
blood vessel development, such as delays in angiogenesis, haemorrhage and early
embryonic lethality [156, 157]. The observation of similar defects when studies were
performed with loss of VEGF signalling in mice and zebrafish suggests that miR-126
modulates VEGF signalling. In endothelial cells, decreased phosphorylation of AKT
and ERK1/2 in response to VEGF treatment was observed in knockdown of miR-126.
MiR-126 targets PIK3R2 and SPRED1, the negative regulators of VEGF pathway
[154, 156–158].
In adults, the roles of miR-126 are quite different [153]. MiR-126 induces
angiogenesis, as well as vascular tissue remodeling in response to vascular injury. It
has been demonstrated by Voellenkle et al.(2012), under hypoxic conditions, the levels
of miR-126 increase [159].
Several studies have been conducted to assign the specific roles to the endothelial
specific miR 126-3p. Although the results of such studies yielded to categorize miR
126-3p an an angiomiR, specific information on the expression of its passanger strand,
miR 126-5p is scarce, therefore requires investigation.
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Figure 1.16 : MiR-126, miR 126* and putative protein sequence of EGFL7 [152].
The host gene of miR 126, epidermal growth factor (EGF)-like domain 7 (Egfl7)
is located on chromosome 9 in humans. Along with the two miRNAs mentioned
before, it encodes EGFL7 that is highly conserved in vertebrates. The 41 kDA
angiogenic factor EGFL7 is specific to endothelial cells. It acts solely on endothelial
cells, binds to components of the extracellular matrix and regulates blood vessel
development via Notch signalling. The protein sequence of EGFL7 is composed
of a putative amino-terminal signal peptide domain, an Emilin-like domain (EMI)
and 2 centrally located EGF-like domains; the centrally located one for Notch
receptor-ligand interactions and the distal one for Ca2+-binding as can be seen in Figure
1.16. These protein motifs are often found in secreted and extracellular matrix–bound
proteins. EGFL7 expression is highest during embryogenic development while after
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birth expression is down-regulated in the vascular system. In adults, significant protein
levels are maintained only in vascularized tissues such as the lung, heart, kidney,
spleen and uterus. In cases of physiological and pathological angiogenesis, increase in
expression levels is observed [160–162].
The role of Egfl7 in sprouting angionesis has been demonstrated by studies conducted
on Egfl7 knock-out mice, in which endothelial cells without EGFL7 had impaired
migration and created clumps and over-sized sprouts instead of proper vessel sprouts.
These findings suggested that EGFL7 created an environment where cells can be
properly positioned to construct new vessels. A study conducted by Schmidt et al.
(2014) has provided a link between Notch signaling and EGFL7 by showing the
binding of EGFL7 to Notch receptors. EGFL7 is suggested to compete with NOTCH
ligands and inhibit NOTCH receptor activation, therefore affect angiogenesis [160].
1.9 Hypothesis
Atherosclerosis related cardiovascular diseases (CVDs) are considered as the number
one cause of death in developed countries. Atherosclerosis begins due to endothelial
dysfunction. Subsequently, leukocyte infiltration and foam cell formation as a
consequence of a deposition of oxidized low-density lipoprotein particles is observed.
As the disease progresses, apoptosis, necrotic core formation, migration and
proliferation of vascular smooth muscle cells together with intraplaque angiogenesis
cause lumenal narrowing. When the fibrous cap structure in the core of the plaques
ruptures, thrombosis causing stroke or myocardial infarction, takes place [163, 164].
Several studies have linked intraplaque angiogenesis with the formation of vulnerable
plaques, which are prone to rupture [14, 15].
Egfl7 and miR-126 are considered as important regulator molecules of angiogenesis.
During embryonic development, miR-126 induces angiogenic signaling, promotes the
differentiation of embryonic stem cells to endothelial cells and endothelial progenitors.
On the other hand, as reviewed by Chistiakov et al.(2016), miR-126 maintains the
vascular homeostasis via inhibition of angiogenesis, just as its host gene Egfl7 is
down-regulated in adults to help in maintenance of the quiescent endothelial phenotype
in terms of angiogenesis. It is suggested that in response to vascular injury or under
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hypoxic conditions, miR-126 is up-regulated for new vessel formation, as well as to
rectruit endothelial progenitor cells that function in vascular repair [153].
Furthermore, the host gene of miR 126, Egfl7 too was found to be up-regulated in
pathological angiogenesis [160–162]. In addition, in response to vascular injury in
rats, Egfl7 was up-regulated as demonstrated by Campagnolo et al.(2005) [165]
In light of the literature reviewed, it is expected to observe Egfl7 and miR-126
up-regulation in carotid artery atherosclerotic plaques, due to the vascular injury
caused by progressive atherosclerosis. In contrast, the expression levels of negative
regulators of VEGF pathways, Spred1 and Pik3r2, are expected to be down-regulated,
since they are targets of miR 126-3p, as suggested in Figure 1.17.
Figure 1.17 : Role of miR-126-3p, SPRED1 and PIK3R2 in angiogenesis [166].
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2. MATERIALS AND METHODS
2.1 Materials
2.1.1 Subjects and specimens
Carotid artery atherosclerotic plaque samples were obtained from patients (n=14)
undergoing carotid endarterectomy for stenosis greater than 70% or stenosis ranging
from 50% to 70% associated to clinical symptoms according to AHA guidelines.
The patients were enrolled at Istanbul Medicana International Hospital. Symptomatic
patients were defined subjects with a history of transient attacks, stroke or amourosis
fugax. The 2-3 cm of plaque area and the tissue from the region immediately adjacent
to plaque were collected from patients. The region immediately adjacent to plaque was
used as control tissue in the experiments. All samples were transferred to cryogenic
tubes immediately after they were obtained and placed in liquid nitrogen. Samples
were transferred to Istanbul University Experimental Medicine Research Institute
(DETAE) Molecular Medicine Department and stored in -80◦C for the subsequent
experiments. This thesis study was performed according to the current version
of Helsinki Declaration. Informed consent was obtained from each patient. The
experiments were reviewed and approved by the Committee of Experimental Medicine
Research Institute at Istanbul University.
2.1.2 Chemicals and kits
All of the purchased chemicals and commercially available kits used in this thesis
study are given in Appendix A with their suppliers. App B lists the ID numbers of the
commercially available TaqMan R©miRNA and gene expression assays.
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2.1.3 Laboratory equipment
The equipment that is used to perform the experimental procedures of this thesis study
is listed in App C.
2.2 Methods
2.2.1 MicroRNA target prediction
The result of thorough literature review pointed out the role of microRNA 126 in
angiogenesis. The miRBase database was searched for microRNA 126 [167]. Together
with data obtained from the literature review, microRNA 126-3p and its passanger
strand, microRNA 126-5p were chosen as the microRNAs to be studied.
Next, the mRNA targets of miR 126-3p were investigated using the TargetScan [123]
and miRTarBase [168] miRNA target prediction databases.
Finally, the mRNA targets were searched in National Center for Biotechnology
Information (NCBI) Gene Database [169]. Supported by the information obtained
from literature review, the genes that were involved in angiogenesis as well as VEGF
signalling pathway were chosen to be studied as mRNA targets of the miR 126-3p.
2.2.2 RNA isolation from samples
For isolation of total RNA and microRNAs from plaque and control samples obtained
from patients, mirVanaTM miRNA Isolation Kit (Ambion, Austin, TX, USA) was used.
For purification of total RNA or small RNAs, this kit combines methods of organic
extraction with acid:phenol:chloroform and solid-phase extraction by immobilization
of RNA on glass-fiber filters. For all RNA isolations, the following protocols were
used:
-Samples were removed from -80◦C and placed on ice immediately to prevent the
release of RNases as a result of partial thawing. The weight of each sample was
measured and for standardization, 100 mg of frozen tissue was used in every isolation.
Using a sterile scalpel, each plaque and control material was divided into two 100
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mg samples; one to be used for isolation of total RNA and the other for isolation of
miRNAs.
-1000 µl of lysis buffer was added to microtubes and tubes were placed on ice.
-For homogenization, tissues were ground to powder with liquid nitrogen in a
pre-chilled pestle and mortar.
-The ground tissues were scraped into lysis buffer containing microtubes on ice using
a prechilled metal spatula and mixed rapidly until all visual clumps were dispersed.
The lysate volume was measured.
-For organic extraction of total RNA and miRNAs, 100 µl of miRNA Homogenate
Additive was mixed with cell lysates, mixed well by vortexing and incubated for 10
minutes on ice.
-Acid:phenol:chloroform with a volume equal to the cell lysate volume before the
addition of miRNA homogenate additive was added to samples and vortexed for 30-60
seconds to mix.
-Samples were centrifuged at room temperature for 5 minutes at 10.000 x g to separate
the aqueous and organic phases.
-The aqueous upper phase was transferred into a new 2 ml microtube without
disturbing the lower phase. The removed volume was noted.
-At this point, two different procedures were used to isolate total RNA and miRNAs.
Total RNA Isolation Procedure
- 1.25 volumes of room temperature 100% ethanol was added to the aqueous phase
which was recovered in the previous step.
- A filter cartridge was placed into a 2 ml collection tube supplied with the kit, the
lysate/ethanol mixture was pipetted onto the filter cartridge and centrifuged for 15
seconds at 10.000 x g to pass the mixture through the filter.
- The flow-through was discarded and the above step was repeated until all of the
lysate/ethanol mixture was passed through the filter.
- 700 µl of wash solution 1 was applied to the filter cartridge and centrifuged for 5-10
seconds. The flow-through was discarded.
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- 500 µl of wash solution 2 was added onto the filter cartridge and centrifuged for 5-10
seconds. The flow-through was discarded. This step was repeated with a second 500
µl aliquot of wash solution 2. After discarding the flow-through, the assembly was
centrifuged for 1 minute to remove the residual fluid from the filter.
- The filter cartridge was transferred into a fresh collection tube. 100 µl of pre-heated
(95◦C) elution solution was applied to the center of the filter and centrifuged for 20-30
seconds at maximum speed to recover the total RNA.
Enrichment Procedure for MicroRNAs
- This enrichment was accomplished by first immobilizing large RNAs on the filter
with a relatively low ethanol concentration and collecting the flow-through containing
mostly small RNA species. To begin with, 1.25 volumes of room temperature 100%
ethanol was added to the aqueous phase which was recovered in the organic extraction
step.
- A filter cartridge was placed into a 2 ml collection tube supplied with the kit, the
lysate/ethanol mixture was pipetted onto the filter cartridge and centrifuged for 15
seconds at 10.000 x g to pass the mixture through the filter.
- The filtrate was collected.
- 2/3 volumes of room temperature 100% ethanol was added to the filtrate, the
filtrate/ethanol mixture was pipetted onto a filter cartridge and centrifuged for 15
seconds at 10.000 x g.
- The flow-through was discarded and the above step was repeated until all the
filtrate/ethanol mixture was passed through the filter.
- 700 µl of wash solution 1 was applied to the filter cartridge and centrifuged for 5-10
seconds. The flow-through was discarded.
- 500 µl of wash solution 2 was added onto the filter cartridge and centrifuged for 5-10
seconds. The flow-through was discarded. This step was repeated with a second 500
µl aliquot of wash solution 2. After discarding the flow-through, the assembly was
centrifuged for 1 minute to remove the residual fluid from the filter.
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- The filter cartridge was transferred into a fresh collection tube. 100 µl of pre-heated
(95◦C) elution solution was applied to the center of the filter and centrifuged for 20-30
seconds at maximum speed to recover the miRNAs.
The purity and quantity of all RNA samples were assessed using the NanoDrop 2000
spectrophotometer (Thermo Scientific, Wilmington, DE, USA). The purity of RNA
samples were assessed from the ratio of A260/A280. Highly pure RNA samples with a
ratio of 1.8 - 2.1 were used. All RNA samples were stored at -20◦C until further use.
2.2.3 Complementary DNA synthesis
To synthesize complementary DNA (cDNA) from plaque and control total RNA
samples, High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster
City CA, USA) was used. The protocol for reverse transcription (RT) reactions is as
follows:
-All the kit components were thawed on ice. For each reaction, a 2X RT master mix
was prepared with the components shown in Table 2.1.
Table 2.1 : Components to Prepare 2X RT Master Mix.
Component Volume per Reaction ( µl )
10X RT Buffer 2.0
25X dNTP Mix (100 mM) 0.8
10X RT Random Primers 2.0
MultiscribeTMReverse Transcriptase 1.0
Nuclease-free H2O 4.2
Total per Reaction 10
-To be able to perform real time quantitative polymerase chain reaction (qRT-PCR)
analyses with the equal concentrations of cDNA, 100 ng of total RNA per reaction was
used for each reaction.
-10 µl of 2X RT mix for each reaction was mixed with 10 µl of total RNA sample.
-The PCR tubes were briefly centrifuged to spin down the contents.
-The samples were loaded into the thermal cycler and the reaction volume was set to
20 µl.
All reverse transcription reactions including the reactions for miRNAs described
in the following paragraphs were performed with BIO-RAD Thermal Cycler
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T100TM(Bio-Rad, Hercules, CA, USA). The conditions used for RT-PCR are given
in Table 2.2.
Table 2.2 : RT-PCR Reaction Conditions for Total RNA Samples.
Step 1 Step 2 Step 3 Step 4
Temperature (◦C) 25 37 85 4
Time 10 min 120 min 5 min ∞
TaqMan R© MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City
CA, USA) was used for syntheses of cDNA from miRNAs isolated from plaque and
control samples. For reverse transcription of miRNA samples, the given protocol was
used:
-All kit component were thawed on ice.
-A RT master mix of 7 µl was prepared using the components shown in Table 2.3.
Table 2.3 : Components to Prepare miRNA RT Master Mix.
Component Volume per Reaction (µl)
10 mM dNTPs (with dTTP) 0.15
MultiscribeTMReverse Transcriptase) 1.0
10X Reverse Transcription Buffer 1.5
RNase Inhibitor, 20U/ 0.19
Nuclease-free H2O 4.16
Total volume 7.0
-The components were mixed gently and centrifuged to bring the solutions to the
bottom of PCR tubes. The tubes were placed on ice.
-MiRNA samples and 5X RT primers were thawed on ice.
-5X RT primers were vortexed to mix and centrifuged.
-7 µl master mix was combined with 5 µl miRNA (10 ng per reaction) for each
reaction.
-3 µl of 5X RT primer was mixed with 12 µl reaction mix to a final volume of 15 µl.
For miRNA reverse transcription reactions, the primers were specific for each of the
TaqMan R©miRNA assays (miRNA-126-3p, miRNA-126-5p and miRNA endogenous
control U6 assays) to be used for the following qRT-PCR reactions. Working with
the same miRNA template, RT-PCR was performed to synthesize cDNA samples for
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miRNA-3p, miRNA-5p and U6, using the different primers specific to each of these
TaqMan R© miRNA assays.
The reaction conditions to perform reverse transcription of microRNA samples are
given in Table 2.4.
Table 2.4 : RT-PCR Reaction Conditions for MicroRNA Samples.
Step 1 Step 2 Step 3 Step 4
Temperature (◦C) 16 42 85 4
Time 30 min 30 min 5 min ∞
Following RT-PCR reactions, obtained cDNA samples were kept in -20 ◦C until
qRT-PCR analyses.
2.2.4 Real time quantitative PCR
Following cDNA syntheses from total RNA and miRNA samples, real time
quantitative PCR (qRT-PCR) reactions were performed to quantify the relative
expression levels of miR-126-3p, miR-126-5p as well as Egfl7, Spred1 and Pik3r2
genes in plaque and control samples.
TaqMan R©miRNA-126-3p and miRNA-126-5p assays (Applied Biosystems, Foster
City CA, USA) were used to detect miRNA-126-3p and miRNA-126-5p expression
levels in plaque and control samples. The levels of small nuclear RNA U6 were also
quantified using Taqman R© endogenous control small nuclear RNA U6 assay (Applied
Biosystems, Foster City CA, USA) for normalizing the levels of miR-126-3p and
miR-126-5p.
The assays were composed of small RNA-specific forward PCR primer, small
RNA-specific reverse PCR primer and small RNA-specific 6-carboxy fluorescein
(FAMTM) dye-labeled Taqman R© probes.
All PCR amplification reactions were carried out in 96-well plates. In one 96-well
plate, 5 plaque and 5 control samples were analyzed in each run. MiR-126-3p and
miR-126-5p assays were run separately. The reactions were performed in a total
volume of 20µl.
To prepare the qPCR reaction;
1. The 96-well plate was placed on ice.
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2. TaqMan R© Assays (20X) and cDNA samples were thawed on ice.
3. The number of reactions needed for each assay were calculated. Each plate included
a TaqMan R© assay (20X) for each cDNA sample, a Taqman R© Endogenous Control
Assay for each cDNA sample and a no template control(NTC). For a plate containing
20 cDNA samples ( 5 plaque and 5 control samples run in duplicates) and 1 NTC, a
reaction mixture for 22 reactions was prepared for each assay.
4. The components shown in Table 2.5 were used to prepare qRT-PCR reaction mix
without the addition of cDNA.
Table 2.5 : Components to Prepare qRT-PCR Reaction Mix for TaqMan R© miRNA
Assays.
Component Volume per 20µl Reaction
TaqMan R© Small RNA Assay (20X) 1.00 µl
TaqMan R©Universal PCR Master Mix 2 10.00 µl
Nuclease-free water 7.67 µl
5. The tube was inverted several times to mix and centrifuged briefly.
6. 1.33 µl of cDNA was pipetted into each of two wells of 96-well plate for each
sample.
7. 18.67 µl of the qRT-PCR reaction mix prepared for each assay was pipetted onto
each cDNA sample that was previously transferred to the 96-well plate wells.
8. The plate was covered with optic seal and centrifuged briefly.
9. The plate was loaded into the instrument.
10. The experiment was set up and the plate was run with the conditions shown in
Table 2.6.
Table 2.6 : qRT-PCR Reaction Conditions for TaqMan R© miRNA Assays.
Stage Temp (◦C) Time (mm:ss)
Hold 50 2:00
Hold 95 10:00
Cycle (40 Cycles)
95 0:15
60 1:00
To detect Egfl7, Spred1 and Pik3r2 gene expression levels in plaque and control
samples, TaqMan R© Gene Expression Assays (Applied Biosystems, Foster City CA,
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USA) were used. Levels of housekeeping gene 18S ribosomal RNA were also
quantified in plaque and control samples for normalizing expression levels of Egfl7,
Spred1 and Pik3r2. For normalization, TaqMan R© Endogenous Control Assay 18S
(Applied Biosystems, Foster City CA, USA) was used. All of the assays were
composed of specific forward and reverse PCR primers and 6-FAMTM dye-labeled
TaqMan R© probes. All the TaqMan R© Gene Expression Assay ID numbers are listed in
App B.
Quantitative Real Time PCR reactions were carried out in 96-well plates. In one
96-well plate, 4 plaque and 4 control cDNA samples were amplified using Egfl7,
Spred1 and Pik3r2 TaqMan R© Gene Expression Assays along with the Endogenous
Control Assay 18S in each run. The reactions were performed in a total volume of
20µl.
To prepare the qPCR reaction;
1. The 96-well plate was placed on ice.
2. TaqMan R© Gene Expression Assays (20X) and cDNA samples were thawed on ice.
3. The number of reactions needed for each assay were calculated. Each plate included
a TaqMan R© Assay (20X) for each cDNA sample, a TaqMan R© Endogenous Control
Assay for each cDNA sample and a no template control(NTC). For a plate containing
16 cDNA samples ( 4 plaque and 4 control samples run in duplicates) and 1 NTC, a
reaction mixture for 18 reactions was prepared for each of the assays.
4. The components shown in Table 2.7 were used to prepare qRT-PCR reaction mix
without the addition of cDNA.
Table 2.7 : Components to Prepare qRT- Reaction Mix for TaqMan R© Gene
Expression Assays.
PCR Reaction Mix Component Volume per 20µl Reaction
TaqMan R© Gene Expression Assay (20X) 1.00 µl
TaqMan R©Universal PCR Master Mix 2 10.00 µl
RNase-free water 5.00 µl
5. The tube was inverted several times to mix and centrifuged briefly.
6. 4.00 µl of cDNA was pipetted into each of two wells of 96-well plate for each
sample.
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7. 16.00 µl of the qRT-PCR reaction mix prepared for each assay was pipetted onto
each cDNA sample that was previously transferred to the 96-well plate wells.
8. The plate was covered with optic seal and centrifuged briefly.
9. The plate was loaded into the instrument.
10. The experiment was set up and the plate was run with the conditions shown in
Table 2.8.
Table 2.8 : qRT-PCR Reaction Conditions for TaqMan R© Gene Expression Assays.
Stage Temp (◦C) Time (mm:ss)
Hold 50 2:00
Hold 95 10:00
Cycle (40 Cycles)
95 0:15
60 1:00
All qRT-PCR reactions were performed with the Mx3005P Real-Time PCR (Agilent,
Santa Clara, USA). Quantitative real-time PCR analysis depends on detection and
quantification of PCR products via fluorescent signals emitted by the dyes used in
the reaction. The principle of this system relies on TaqMan R© probes. As integral parts
of the TaqMan R© assays used in the qRT-PCR reactions, TaqMan R© probes are linear
oligonucleotides labeled with a fluorescent reporter dye on the 5’ end and a quencher
dye on the 3’ end. The signal from the reporter molecule is quenched when both
of the molecules are in close proximity in the solution. In contrast, when the probe
is hybridized to its target sequence, it is cleaved by the 5’ nuclease activity of the
Taq polymerase during the extension phase of the PCR. A fluorescence signal based
on the fluorescence resonance energy transfer (FRET) principle is emitted when the
reporter and quencher molecules are separated. In each PCR cycle, reporter molecules
are separated from their probes and as a result, fluorescence intensity increases
proportionally with the amount of amplified template. The increase in fluorescence
signal is detected in real time by the instrument. During amplification, data on about
the fluorescence emission is collected by the software of the instrument and output is
shown as amplification plots [170, 171].
QRT-PCR amplification is comprised of four successive phases: The baseline phase;
the exponential phase; the linear phase and the plateau. The exponential amplification
of the template begins during the PCR cycles of baseline phase.This phase is named
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Figure 2.1 : Single amplification plot [171].
so because the accumulating fluorescent signals are below the detection limits of the
instrument. During the run, the instrument software calculates a ∆Rn value and plots
it versus the cycle number as shown in Figure 2.1. The ∆Rn value is calculated by the
equation shown below (2.1) in which Rnf is the fluorescence emission of the product
at each time point and Rnb is the fluorescence emission of the baseline:
Rn= Rn f −Rnb (2.1)
Based on the baseline, a threshold is chosen by the software and a fluorescent signal
detected above the threshold can be used to define the threshold cycle (Ct) for a
sample.CT points to the amplification of template molecule and represents a cycle
at which the sample fluorescence signal from the sample exceeds a chosen threshold
above background fluorescence signal. PCR amplification continues at maximal rate
during the exponential phase in which the earliest detectable signals are received. In a
reaction that is 100% efficient, 2 complete molecules are synthesized from every one
template molecule during the exponential phase. In the linear phase, the amplification
efficiency starts to diminish. In the latest plateau phase, no further increase in signals
take place [172].
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Following qRT-PCR runs, the raw CT values were used for the analysis of gene
expression levels.
2.2.5 Analysis of gene expression
Relative quantification strategy, also known as comparative quantification, was
employed for qRT-PCR analyses. This method quantifies the changes in mRNA
expression levels of a gene or genes in many samples. The change is expressed
relative to the expression levels of a reference gene or genes, such as housekeeping
genes. For this reason, standards with known concentrations are not needed in relative
quantification strategy, as is needed for absolute quantification [173]. In addition, the
studied gene expression levels can be quantified relative to those of healthy individuals
or non-treated controls [174]. The 2∆∆CT method [175], the mathematical model of
normalized gene expression, was used for relative quantification. The alternative
mathematical model is the model with kinetic PCR efficiency correction as can be
observed in Figure 2.2 [173].
Figure 2.2 : Quantitative real time PCR strategies for quantification of gene
expression [173].
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Quantitative real time PCR quantifies the mRNA levels differentially. Many factors,
such as biological conditions (pathologies, diseased state...etc.) and non-reproducible
factors that are non-specific to the biological conditions contribute to this differential
expression. Although all the technical variables are carefully controlled, variations
from sample to sample and from run to run still cause the aforementioned factors.
Therefore, data normalization with the help of internal reference genes is very
important in qRT-PCR, since it minimizes the effects of these non-specific factors.
Housekeeping genes, genes that are needed for survival and that are expressed stably
and abundantly, are chosen as internal reference genes [176]. Most commonly used
internal reference genes include, Beta actin (ACTB), Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), 18S ribosomal RNA (18S), Phosphoglycerate kinase 1
(PGK1), Peptidylprolyl isomerase A (PPIA) and TATA box binding protein (TBP)
[176, 177]. In addition to internal reference genes mentioned before, housekeeping
genes used for normalization of miRNA expression exist. Let-7a, miR-16, small
nuclear RNA (snRNA) U6 are among the housekeeping genes used for normalization
of miRNA expression levels [178].
2∆∆CT model was chosen to be used in the relative quantification strategy employed.
For normalization of gene expression and miRNA expression, 18S rRNA and U6
snRNA were used. All of the target gene and miRNA expression levels of plaque
samples were compared to those of control samples and normalized to the levels of the
18S rRNA and U6 snRNA (U6) using the following procedure and equations:
- Mean CT values for Egfl7, Spred1, Pik3r2 genes as well as housekeeping gene 18S
measured in each of the control and plaque samples were exported to Microsoft Excel
following qRT-PCR experiments.
- For each plaque and control sample, ∆CT values were calculated for Egfl7, Spred1,
Pik3r2 target genes using their respective CT values with the equations (2.2) and (2.3).
∆CtPlaque =CtTargetgene−CtRe f erence (2.2)
∆CtControl =CtTargetgene−CtRe f erence (2.3)
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-For each sample, ∆∆CT values were calculated for Egfl7, Spred1, Pik3r2 target genes
using the equation (2.4)below.
∆∆Ct = ∆CtPlaque−∆CtControl (2.4)
-The relative quantification ratio R was calculated for each target gene by the equation
(2.5).
R= 2∆∆Ct (2.5)
-For each target gene, differences in expression levels were denoted as log-transformed
ratios to show fold change between the carotid artery plaque tissues and control tissue.
Following qRT-PCR analyses, mean CT values for miR 126-3p, miR 126-5p and
the housekeeping gene snU6 measured in each of the control and plaque samples
were exported to Microsoft Excel following qRT-PCR experiments. The procedures
explained above were replicated for the analyses of miR 126-5p and miR 126-3p
expression levels in plaques and controls. The expression levels in plaque samples
relative to controls were expressed as fold change values.
2.2.6 Statistical analysis
To perform statistical analyses, IBM SPSS Statistics for Windows, version 20.0
software (IBM Corp., Armonk, NY) was used. The significance of differences
between the results from plaque and control tissues was examined with Student’s t test.
Demographic information was compared with gene expression data expressed as fold
change by using Chi-square and Fisher’s Exact tests. Values were expressed as mean
± standard deviation (SD). P values less than 0.05 denoted statistical significance.
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3. RESULTS
3.1 Analysis of the Clinical Parameters of the Study Population
The demographic and biochemical features of the study population (n=14) were
obtained from the surgical team who have performed the carotid endarterectomy
operations on patients in Istanbul Medicana International Hospital. The data, including
gender, age, body mass index (BMI) of patients, as well as their smoking habits, the
presence of major cardiovascular risk factors, the presence of other cardiovascular
diseases and their statin use is reported in Table 3.1 below.
Table 3.1 : Demographical and Clinical Characteristics of the Studied Patients.
Parameters Total (n=14)
Gender (F/M) 9/5
Age (year ± SD) 66.50 ± 7.41
BMI (kg/m ± SD) 30.62 ± 2.60
Smokers n(%) 50
Family History of CVD n (%) 57.1
Diabetes n (%) 42.9
Hypertension n (%) 78.6
Cerebrovascular Event n (%) 64.3
Coronary Artery Disease n (%) 35.7
Peripheral Artery Disease n (%) 28.6
Cholesterol (mmol/L)± SD (mg/dl) 223.57 ± 79.57
LDL Cholesterol ± SD (mg/dl) 141.86 ± 70.97
HDL Cholesterol ± SD (mg/dl) 39.64 ± 10.47
Triglycerides ± SD (mg/dl) 30.62 ± 2.60
Use of Statin n (%) 35.7
n: number of individuals
Values are reported as mean ± standart deviation (SD) or
number of patients ( percentage of the total group )
BMI: Body mass index
CVD: Cardiovascular disease
LDL: Low density lipoprotein
HDL: High density lipoprotein
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Age and male sex are among the major risk factors for atherosclerotic cardiovascular
diseases, although the risk for females after the menopause is almost the same as men
with the same age. The population pyramid that shows the age and sex information
about the study group is given is Figure 3.1 below. As can be seen in the graphic,
64.3% of the study population is female within the age groups 55-60, 60-64,65-69 and
75-80.
Figure 3.1 : Age-sex graphic of the study population.
Figure 3.2 shows the distribution of body mass index values among the patients. The
mean BMI was 30.62 ± 2.60, while the median value for BMI was 30.30 (25.9-37.5).
These values mean that the majority of the patients in the study group were obese.
The following Figure 3.3 demonstrates the fact that being overweight and obese are
linked with metabolic syndrome. The factors that have a tendency to occur together in
metabolic syndrome, named as metabolic risk factors are;
• A large waistline
• Hypertension
• High fasting blood sugar
• A high blood triglyceride level
• A low blood HDL cholesterol level [179].
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Figure 3.2 : Distribution of BMI among the patients.
The distribution of body mass index values among the patients with hypertension is
demonstrated in Figure 3.3. According to the data, 54.4 % of the patients with BMI
between 30-34.9 and 9.1 % of the patients with BMI between 35-39.9 (obese patients)
were hypertensive. Hypertension was also observed in 9.1 % of patients with BMI
between 25-25.9 and in 27.3 % of patients with BMI between 26-29.9 (overweight
patients).
Similarly, as can be seen in Figure 3.3, along with hypertension, overweight and obese
patients also had diabetes mellitus (DM). 16.7 % of the patients who were overweight
had DM, while 16.7 % of the patients within the BMI range of 30-34.9 and classified as
obese were diabetic. Also, 16.7 % of the obese patients within BMI range of 35-39.9
had DM.
The overweight and obese patients not only had hypertension and DM, but also
suffered from high blood cholesterol or abnormal levels of lipids in blood as well,
as in the case of metabolic syndrome explained above. 50 % of the obese patients
within the BMI range of 30-34.9 had dyslipidemia, and 12.5 % of the rest of the obese
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Figure 3.3 : Distribution of BMI among the patients with hypertension, diabetes
mellitus and dyslipidemia.
patients within the BMI range of 35-39.9 suffered from dyslipidemia. Dyslipidemia
was also observed in 37.5 % overweight patients.
Studies have pointed out to the fact that atherosclerotis is a systemic disease, therefore
it has been suggested that the risk factors for its development in carotid arteries
and coronary arteries, as well as its manifestations in both arterial systems would
share similarities to some extent [180]. In a study in which patients were followed
up for three years, it has been observed that myocardial infarction, stroke, vascular
death or re-hospitalization rate were 25.5% for patients who had disease in one
arterial system, while the same rates were 40.5% for patients with disease in multiple
arterial systems [181]. Therefore, the presence of cardiovascular diseases other
than carotid artery disease were investigated in patients. In Figure 3.4, it can be
seen that 35.7% of the patients who suffered from carotid artery atherosclerosis
had also atherosclerotic disease in their coronary arteries. In a similar fashion,
28.6 % of these patients suffered from peripheral artery disease. Because coronary
endothelial dysfunction- atherosclerosis- has been associated with an elevated risk
of cerebrovascular event, such as stroke [182], the percentage of patients who have
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Figure 3.4 : Presence of other cardiovascular diseases in patients.
had a previous cerebrovascular event has also been demonstrated in Figure 3.4.
According to the data, 64.3% who underwent carotid endarterectomy have had a
previous cerebrovascular event. 1 out of 14 patients who has had a cerebrovascular
event had disease in both the carotid and coronary arteries, while 3 patients who has
had a cerebrovascular event also had peripheral artery disease. This data demonstrates
the correspondence between the atherosclerotic disease in different arterial systems.
3.2 MicroRNA 126 Target mRNA Prediction
Literature review on angiogenesis, on the role of microRNAs in angiogenesis and
the so called "angiomiRs" led miRNA 126-3p and its passenger strand -5p to be
investigated in carotid atherosclerotic plaques, along with their target genes in this
study.
The first and the most comprehensive microRNA database, the mirBase was searched
for miRNA 126 [167]. Information on annotation, genome context and its stem
loop structure was obtained on miRNA 126 as shown in Figure 3.5. Coinciding
with literature information, miRNA 126 was termed as a human microRNA which
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is expressed in endothelial cells exclusively and identified as a miRNA taking part in
angiogenetic processes.
Figure 3.5 : MicroRNA 126 [167].
Figure 3.6 : Continued; microRNA 126-3p [167].
Next, mRNA targets for miRNA 126-3p was investigated. For this purpose,
mirTarBase and TargetScan databases were used out of the suggested databases in
mirBase, which function in investigation of miRNA validated targets as well as
predicted targets.
First of all, mirTarBase database was searched for mRNA targets of miRNA 126-3p.
This database lists all the mRNA targets of certain miRNAs and the methods that were
used for validation. The validation methods, such as reporter assay, Western blot and
qPCR are listed under the category "strong evidence". On the other hand, methods
including microarray, next generation sequencing and pulsed stable isotope labelling
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by/with amino acids in cell culture are categorized as "less strong evidence" [168].
Figures 3.7, 3.8 and 3.9 show all the validated mRNA targets of miRNA 126-3p.
Figure 3.7 : Validated targets of microRNA 126-3p [184].
Figure 3.8 : Continued; validated targets of microRNA 126-3p [184].
All of the miRNA 126-3p targets that have been marked under the first category
were checked using Pathways from Biosystems under NCBI Gene Database [183].
The genes encoding proteins that are interacting with VEGF signalling pathway have
been investigated. As a result, Sprouty-related EVH1 domain-containing protein 1
(SPRED1) and Phosphatidylinositol 3-kinase regulatory subunit beta (PIK3R2) were
the chosen miRNA 126-3p targets to be studied.
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As is demonstrated in Figure 3.7, SPRED1 was identified as one of the validated
miRNA 126-3p targets by miRTarBase.
Figure 3.9 : Continued 2; validated targets of microRNA 126-3p [184].
One other validated miRNA 126-3p target among the targets in miRTarBase which
was found to take part in VEGF pathway was PIK3R2. As demonstrated in Figure 3.8,
similar to SPRED1, strong evidence methods were used to validate the interaction of
miRNA 126-3p with PIK3R2.
In addition to SPRED1 and PIK3R2, Epidermal growth factor (EGF)-like domain 7
(EGFL7) was also identified as a validated target of miRNA 126-3p by miRTarBase,
as is demonstrated in Figure 3.9. EGFL7 is an angiogenic factor that has important
regulatory roles in development of blood vessels during the embryogenic and
post-natal stages. Two microRNAs, miR 126-3p and its passanger strand miR
126-5p are encoded from the intron of Egfl7 gene [160]. Egfl7 levels are observed
to be high during the active proliferating state of the endothelium, such as during
embryonic vascular development and physiologic angiogenesis. However, in the adult
endothelium, expression of Egfl7 is mostly down-regulated. The expression levels
of Egfl7 are suggested to increase in cases of pathological angiogenesis, such as
atherosclerosis, in adults [161]. Therefore, in addition to the miRNAs it encodes
from its intron, Egfl7 was chosen as a target gene whose expression levels are to be
investigated in carotid atherosclerotic plaques.
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Figure 3.10 : Predicted targets of microRNA 126-3p [187].
Figure 3.11 : Continued; predicted targets of microRNA 126-3p [187].
Figure 3.12 : Continued 2; predicted targets of microRNA 126-3p [187].
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The miRNA targets were checked with TargetScan database as well. TargetScan lists
all the predicted mRNA targets of certain miRNAs with their conserved and poorly
conserved sites. In addition, values such as, total context score, aggregate probability
of conserved targeting (PCT) are also given in results. Context score is identified as the
total contributions of site type, 3’ pairing, local AU, position, target site abundance and
seed pairing stability [144]. TargetScan provides links to sites in untranslated regions
(UTRs).
Along with the validated miR 126-3p targets that were found by using miRTarBase,
TargetScan database was also used for prediction of miR 126-3p targets. SPRED1,
PIK3R2 and EGFL7 were among the predicted targets of miR 126-3p when TargetScan
database was used. Figures 3.10, 3.11 and 3.12 demonstrate the results obtained by
using TargetScan database for miR 126-3p target prediction.
3.3 Results of RNA Isolations
Following total RNA and miRNA isolations from 14 atherosclerotic plaques and from
14 plaque adjacent control regions, the purity and quantity of all RNA samples were
assessed. The purity of RNA samples are evaluated via the ratio of absorbance at 260
nanometer(nm) and 280 nm, which is referred as the 260/280 value. A 260/280 value
of approximately 2 is accepted as pure for RNA samples [188].
Table 3.2 shows the concentrations (ng/µl) and purities (260/280) of total RNAs
isolated from 14 carotid atherosclerotic plaque samples.
Table 3.2 : The Quantity and Purity of Plaque Total RNA Samples.
Patient Sample No RNA Concentration(ng/µl) 260/280 nm
1 209.8 2.08
2 65.5 2.03
3 39.8 2.12
4 195.0 1.91
5 60.9 1.98
6 196.0 2.00
7 186.0 2.02
8 201.0 2.07
9 106.6 2.06
10 34.1 1.99
11 79.8 2.02
12 134.8 1.86
13 18.7 2.01
14 22.9 2.05
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The total RNA concentrations and purities of 14 control samples are given in Table
3.3.
Table 3.3 : The Quantity and Purity of Control Total RNA Samples.
Patient Sample No RNA Concentration(ng/µl) 260/280 nm
1 75.5 1.94
2 43.0 1.96
3 49.0 2.00
4 18.1 1.85
5 24.4 1.92
6 124.1 1.99
7 140.8 2.04
8 9.9 1.92
9 28.5 2.08
10 49.0 1.98
11 76.1 1.99
12 274.7 1.99
13 26.2 2.07
14 10.3 1.96
Table 3.4 : The Quantity and Purity of Plaque MiRNA Samples.
Patient Sample No RNA Concentration(ng/µl) 260/280 nm
1 101.5 1.99
2 52.4 2.02
3 94.6 2.04
4 22.8 1.92
5 21.5 1.96
6 140.8 1.99
7 135.1 2.05
8 50.9 2.01
9 140.3 2.02
10 27.7 2.01
11 36.7 2.02
12 30.8 1.88
13 29.3 1.87
14 86.1 2.03
Table 3.5 : The Quantity and Purity of Control MiRNA Samples.
Patient Sample No RNA Concentration(ng/µl) 260/280 nm
1 24.8 2.03
2 44.2 1.83
3 48.12 2.04
4 28.3 1.97
5 24.2 1.79
6 43.5 1.87
7 81.6 1.93
8 26.1 1.86
9 44.4 1.88
10 73.6 1.90
11 50.7 1.95
12 26.7 1.84
13 41.5 1.94
14 20.2 1.93
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Table 3.4 shows the concentrations (ng/µl) and purities (260/280) of miRNAs isolated
from 14 carotid atherosclerotic plaque samples.
Finally, the results of miRNA isolations performed on 14 adjacent to plaque control
samples are demonstrated in Table 3.5, with the concentrations (ng/µl) and purities
(260/280).
3.4 Results of Real Time Quantitative PCR
Table 3.6 : Analysis of CT Values for Calculating Spred1 Relative Gene Expression.
Sample
18S Spred1
CT Mean CT Mean ∆CT Mean ∆ ∆ CT 2∆∆CT Fold Change
Control 1 9.04 26.93 17.89
Sample 1 7.80 25.29 17.49 -0.40 1.32 0.28
Control 2 13.28 36.01 22.73
Sample 2 9.33 27.72 18.39 -4.34 20.25 3.01
Control 3 7.71 25.60 17.89
Sample 3 9.65 28.95 19.30 1.41 0.38 -0.98
Control 4 10.38 27.83 17.45
Sample 4 13.56 31.53 17.97 0.52 0.70 -0.36
Control 5 11.80 29.23 17.43
Sample 5 9.37 28.15 18.78 1.35 0.39 -0.94
Control 6 8.39 26.11 17.72
Sample 6 8.28 26.44 18.16 0.44 0.74 -0.30
Control 7 5.51 24.56 19.05
Sample 7 7.15 24.91 17.76 -1.29 2.45 0.89
Control 8 10.00 27.18 17.18
Sample 8 5.51 23.58 18.07 0.89 0.54 -0.62
Control 9 9.89 31.04 21.15
Sample 9 8.00 27.04 19.04 -2.11 4.32 1.46
Control 10 10.90 32.59 21.69
Sample 10 15.29 34.19 18.90 -2.79 6.92 1.93
Control 11 13.59 35.10 21.51
Sample 11 10.83 29.53 18.70 -2.81 7.01 1.95
Control 12 11.75 29.24 17.49
Sample 12 10.93 29.32 18.39 0.90 0.54 -0.62
Control 13 15.76 38.51 22.75
Sample 13 15.56 35.26 19.70 -3.05 8.28 2.11
Control 14 14.54 30.81 16.27
Sample 14 9.41 27.34 17.93 1.66 0.32 -1.15
Following qRT-PCR runs, the raw CT values were obtained from the Mx3005P
Real-Time PCR instrument software. The qRT-PCR runs for genes Egfl7, Spred1,
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Table 3.7 : Analysis of CT Values for Calculating Pik3r2 Relative Gene Expression.
Sample
18S Pik3r2
CT Mean CT Mean ∆CT Mean ∆ ∆ CT 2∆∆CT Fold Change
Control 1 9.04 25.28 16.24
Sample 1 7.80 24.96 17.16 0.92 0.53 -0.64
Control 2 13.28 34.92 21.64
Sample 2 9.33 26.49 17.16 -4.48 22.32 3.11
Control 3 7.71 24.55 16.84
Sample 3 9.65 27.35 17.70 0.86 0.55 -0.60
Control 4 10.38 27.14 16.76
Sample 4 13.56 30.79 17.23 0.47 0.72 -0.33
Control 5 11.80 28.24 16.44
Sample 5 9.37 26.96 17.59 1.15 0.45 -0.80
Control 6 8.39 26.36 17.97
Sample 6 8.28 26.29 18.01 0.04 0.97 -0.23
Control 7 5.51 24.04 18.53
Sample 7 7.15 24.79 17.64 -0.89 1.85 0.62
Control 8 10.00 27.25 17.25
Sample 8 5.51 23.50 17.99 0.74 0.60 -0.51
Control 9 9.89 30.77 20.88
Sample 9 8.00 27.72 19.72 -1.16 2.23 0.80
Control 10 10.90 29.26 18.36
Sample 10 15.29 34.03 18.74 0.38 0.77 -0.26
Control 11 13.59 34.82 21.23
Sample 11 10.83 29.26 18.43 -2.80 6.96 1.94
Control 12 11.75 29.44 17.69
Sample 12 10.93 29.10 18.17 0.48 0.72 -0.33
Control 13 15.76 36.25 20.49
Sample 13 15.56 34.61 19.05 -1.44 2.71 1.00
Control 14 14.54 30.78 16.24
Sample 14 9.41 26.94 17.53 1.29 0.41 -0.89
Pik3r2 and 18S in plaques and controls were completed first. Since reactions were run
in duplicates, mean CT values of the duplicates were calculated.
Relative quantification employing the 2∆∆CT method [175] was used for analyses of
Egfl7, Spred1 and Pik3r2 gene expression levels. The calculated mean CT values of
target genes and the housekeeping gene 18S in controls and in plaque samples were
exported to Microsoft Excel for calculation of ∆CT, ∆∆CT, the relative quantification
ratio R ( 2∆∆CT ) and finally for the log-transformed ratios showing the fold change.
The tables 3.6, 3.7 and 3.8 show the calculated ∆CT, ∆∆CT, 2∆∆CT ) and fold change
values for Spred1, Pik3r2 and Egfl7, respectively.
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Table 3.8 : Analysis of CT Values for Calculating Egfl7 Relative Gene Expression.
Sample
18S Egfl7
CT Mean CT Mean ∆CT Mean ∆ ∆ CT 2∆∆CT Fold Change
Control 1 9.04 29.21 20.17
Sample 1 7.80 26.92 19.12 -1.05 2.07 0.73
Control 2 13.28 36.84 23.56
Sample 2 9.33 28.52 19.19 -4.37 20.68 3.03
Control 3 7.71 29.04 21.33
Sample 3 9.65 29.24 19.59 -1.74 3.34 1.21
Control 4 10.38 32.47 22.09
Sample 4 13.56 35.47 21.91 -0.18 1.13 0.12
Control 5 11.80 33.48 21.68
Sample 5 9.37 34.1 24.73 3.05 0.12 -2.11
Control 6 8.39 27.75 19.36
Sample 6 8.28 26.59 18.31 -1.05 2.07 0.73
Control 7 5.51 26.53 21.02
Sample 7 7.15 24.81 17.66 -3.36 10.27 2.33
Control 8 10.00 32.67 22.67
Sample 8 5.51 23.99 18.48 -4.19 18.25 2.90
Control 9 9.89 32.11 22.22
Sample 9 8.00 26.25 18.25 -3.97 15.67 2.75
Control 10 10.90 37.37 26.47
Sample 10 15.29 39.62 24.33 -2.14 4.41 1.48
Control 11 13.59 36.88 23.29
Sample 11 10.83 30.05 19.22 -4.07 16.80 2.82
Control 12 11.75 30.93 19.18
Sample 12 10.93 30.12 19.19 0.01 0.99 -0.41
Control 13 15.76 42.14 26.38
Sample 13 15.56 37.99 22.43 -3.95 15.45 2.74
Control 14 14.54 34.61 20.07
Sample 14 9.41 30.04 20.63 0.56 0.68 -0.39
Next, miRNA 126-3p and miRNA 126-5p expression levels were calculated by the
relative quantification method. After running qRT-PCR experiments for miRNA
126-3P in plaques and controls, miRNA 126-5p was completed as well. Once the
raw CT values were obtained from the instrument software, mean CT values of the
duplicates were calculated. Similar to the target genes, the mean CT values of miRNA
126-3p and -5p were exported to Microsoft Excel for calculation of ∆CT, ∆∆CT, 2∆∆CT
and the fold change. The tables 3.9 and 3.10 show the calculated ∆CT, ∆∆CT, 2∆∆CT )
and fold change values for miRNA 126-3p and miRNA 126-5p, respectively.
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Table 3.9 : Analysis of CT Values for Calculating miR 126-3p Expression in plaques
relative to controls.
Sample
18S miR 126-3p
CT Mean CT Mean ∆CT Mean ∆ ∆ CT 2∆∆CT Fold Change
Control 1 18.17 20.62 2.45
Sample 1 19.92 21.98 2.06 -.39 1.31 0.27
Control 2 20.11 22.80 2.69
Sample 2 22.73 24.93 2.20 -0.49 1.40 0.34
Control 3 20.24 22.66 2.42
Sample 3 21.61 19.63 -1.98 -4.40 21.11 3.05
Control 4 18.64 24.06 5.42
Sample 4 20.75 29.19 8.44 3.02 0.12 -2.09
Control 5 20.66 23.22 2.56
Sample 5 17.29 18.64 1.35 -1.21 2.31 0.84
Control 6 18.42 21.50 3.08
Sample 6 20.31 21.72 1.41 -1.67 3.18 1.16
Control 7 21.52 24.67 3.15
Sample 7 21.25 22.04 0.79 -2.36 5.13 1.64
Control 8 20.46 21.08 0.62
Sample 8 19.77 20.55 0.78 0.16 0.90 -0.11
Control 9 22.11 24.35 2.24
Sample 9 23.22 22.52 -0.70 -2.94 7.67 2.04
Control 10 21.40 35.15 13.75
Sample 10 25.54 28.65 3.11 -10.64 1,595.73 7.38
Control 11 23.79 31.47 7.68
Sample 11 22.20 18.92 -3.28 -10.96 1,992.00 7.60
Control 12 23.21 28.83 5.62
Sample 12 18.82 18.93 0.11 -5.51 45.57 3.82
Control 13 23.20 34.74 11.54
Sample 13 23.15 22.19 -0.96 -12.50 5,792.62 8.66
Control 14 24.57 24.54 -0.03
Sample 14 23.23 29.82 6.59 6.62 0.01 -4.59
3.5 Analyses of Target Gene and MicroRNA Expression Levels in Carotid Artery
Atherosclerotic Plaques
Fourteen advanced atherosclerotic plaque samples obtained from carotid artery disease
patients and fourteen respective adjacent regions of plaques as control samples were
used in this thesis study.
Following RNA isolation from tissue samples and cDNA synthesis steps, real time
quantitative PCR analyses were performed to investigate the expression levels of Eglf7,
miR-126-5p, Spred1, Pik3r2 and miR-126-3p in plaque and control samples.
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Table 3.10 : Analysis of CT Values for Calculating miR 126-5p Expression in plaques
relative to controls.
Sample
18S miR 126-5p
CT Mean CT Mean ∆CT Mean ∆ ∆ CT 2∆∆CT Fold Change
Control 1 32.01 30.48 -1.53
Sample 1 29.93 30.36 0.43 1.96 0.26 -1.36
Control 2 26.66 35.79 9.13
Sample 2 27.52 33.20 5.68 -3.45 10.93 2.39
Control 3 33.70 33.38 -0.32
Sample 3 36.63 36.70 0.07 0.39 0.76 -0.27
Control 4 22.94 22.60 -0.34
Sample 4 21.27 21.22 -0.05 0.29 0.82 -0.20
Control 5 26.24 34.42 8.18
Sample 5 33.31 34.72 1.41 -6.77 109.14 4.69
Control 6 31.46 31.18 -0.28
Sample 6 31.90 31.14 -0.76 -0.48 1.39 0.33
Control 7 24.30 28.04 3.74
Sample 7 33.60 34.03 0.43 -3.31 9.92 2.29
Control 8 21.56 22.25 0.69
Sample 8 27.42 22.88 -4.54 -5.23 37.53 3.63
Control 9 21.99 21.45 -0.54
Sample 9 20.56 23.49 2.93 3.47 0.09 -2.41
Control 10 21.40 35.15 13.75
Sample 10 24.60 37.76 13.16 -0.59 1.51 0.41
Control 11 23.79 31.47 7.68
Sample 11 24.29 29.48 5.19 -2.49 5.62 1.73
Control 12 23.21 28.83 5.62
Sample 12 21.04 29.83 8.79 3.17 0.11 -2.20
Control 13 23.20 34.74 11.54
Sample 13 23.98 32.00 8.02 -3.52 11.47 2.44
Control 14 24.57 24.54 -0.03
Sample 14 23.94 23.94 4.00 0.30 0.98 -0.92
The 2∆∆CT method was used for comparing Eglf7, Spred1 and Pik3r2 gene expression
levels as well as miR 126 -3p and miR 126-5p expression levels of plaque samples to
those of control samples and for normalizing to the levels of the endogenous controls
18S rRNA and snRNA U6.
3.6 Egfl7 and MiR-126-5p
The expression levels of Egfl7 in fourteen plaque samples are reported individually
with respect to those of the control samples. Egfl7 was up-regulated in eleven samples
as is demonstrated in Figure 3.13.
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Figure 3.13 : Relative gene expression levels of Egfl7.
Figure 3.14 : Relative gene expression levels of miRNA 126-5p.
Similarly, miR-126-5p expression levels in fourteen plaque samples are demonstrated
individually with respect to those of the control samples. MiRNA 126-5p appeared to
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Figure 3.15 : Relative gene expression levels of Egfl7 and miRNA 126-5p.
be down-regulated in six samples, while up-regulation was observed in eight samples.
The results are shown in Figure 3.14.
Figure 3.16 : Overall relative gene expression levels of Egfl7 and miRNA 126-5p.
72
The expression levels of miRNA 126-5p was expected to coincide with the expression
levels of Egfl7. Although this was the case in nine samples, Egfl7 up-regulation was
observed in four samples, while miRNA 126-5p was down-regulated in the very same
samples. Conversely, miRNA 126-p was up-regulated in one sample, as Egfl7 was
down-regulated in the same sample. The possible reasons for differences in expression
levels will be discussed later in the following section. The comparison of expression
levels of miRNA 126-5p and Egfl7 are shown in Figure 3.15.
The overall Egfl7 mRNA expression was higher in plaques (p <0.001) compared to
controls. MiR 126-5p expression was also higher in plaques with respect to control
regions, but not reaching statistical significance (p= 0.751) as demonstrated in Figure
3.16.
3.6.1 Statistical correlation of egfl7 and miR-126-5p expression levels with clinical
parameters of patients
The correlation between Egfl7 and miR-126-5p expression levels and clinical
parameters of patients was investigated using IBM SPSS Statistics for Windows,
version 20.0 software. To to find a correlation between relative gene expression
levels of Egfl7 and miR-126-5p and the clinical parameters of patients, the study
population was separated into two groups; those with low expression levels of Egfl7
and miR-126-5p and those with high expression levels of Egfl7 and miR-126-5p. For
the expression levels of Egfl7 and miR-126-5p, above 1.32 and 0.82 fold change
cut-off values, respectively, were considered as “high” level changes. Expression
levels of Egfl7 and miR-126-5p in patients did not appear to be statistically associated
with the tested cardiovascular risk factors such as being female, BMI>25, smoking,
family history of cardiovascular diseases, hypertension, diabetes, presence of a
cerebrovascular event, coronary artery and peripheral artery disease (Table 3.1).
However, a positive correlation was found between the high levels of miR-126-5p and
elevated levels of LDL cholesterol (p=0.023) (Table 3.11).
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3.7 Spred1, Pik3r2 and MiR-126-3p
The analyses of Spred1, Pik3r2 and miR-126-3p expression levels in plaque and
control samples was performed with real time quantitative PCR.
The relative gene expression levels of Spred1 in fourteen plaque samples is
demonstrated in Figure 3.17. Spred1 up-regulation was observed in six of the
atherosclerotic plaque samples, while it was down-regulated in eight samples.
Figure 3.17 : Relative gene expression levels of Spred1.
In addition, Pik3r2 was down-regulated in nine out of fourteen samples. The gene
expression levels of Pik3r2 in each of the samples is shown in Figure 3.18.
In the case of miR-126-3p, up-regulation was observed in eleven samples as
demonstrated in Figure 3.19.
As expected, decrease in expression levels of Spred1 and Pik3r2 was observed
whenever miR-126-3p expression level increased as shown in Figure 3.20.
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Figure 3.18 : Relative gene expression levels of Pik3r2.
Figure 3.19 : Relative gene expression levels of miRNA 126-3p.
Compared to the control regions, the overall miR-126-3p expression was higher in
plaques (p <0.05) as depicted in Figure 3.21. Spred1 and Pik3r2 overall expressions
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Figure 3.20 : Relative gene expression levels of Spred1, Pik3r2 and miRNA 126-3p.
were also higher in plaques with respect to control regions, but the up-regulations were
not found to be statistically significant.
Figure 3.21 : Overall relative gene expression levels of Spred1, Pik3r2 and miRNA
126-3p.
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3.7.1 Statistical correlation of spred1, pik3r2 and miR-126-5p expression levels
with clinical parameters of patients
The correlation between Spred1, Pik3r2, miR-126-5p expression levels and clinical
parameters of patients was also investigated using IBM SPSS Statistics for Windows,
version 20.0 software. To to find a correlation between relative gene expression levels
of studied genes as well as the miRNA and the clinical parameters of patients, the
study population was separated into two groups; those with low expression levels of
Spred1, Pik3r2 and miR-126-3p and those with high expression levels of Spred1,
Pik3r2 and miR-126-3p. Expression levels of Spred1, Pik3r2 and miR-126-3p in
patients did not appear to be statistically associated with the tested cardiovascular
risk factors such as being female, BMI>25, smoking, family history of cardiovascular
diseases, hypertension, diabetes, presence of a cerebrovascular event, coronary artery
and peripheral artery disease. On the other hand, as demonstrated in Table 3.12, a
positive correlation between the up-regulation of Pik3r2 and elevated levels of LDL
cholesterol was found (p=0.044).
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4. DISCUSSION
Blood vessel formation during the embryonic and post-natal stages or in the adults
takes place by the processes of vasculogenesis and angiogenesis, respectively.
Vasculogenesis refers to the generation of blood vessels from scratch, via the
differentiation of progenitor cells into the endothelial cells. In vasculogenesis,
endothelial progenitor cells in circulation are directed to sites of endothelial damage
and differentiate to endothelial cells for damage repair [189]. Conversely, in
the process of angiogenesis, new blood vessels are formed from the existing
vasculature. Angiogenesis includes the processes of proliferation, sprouting, migration
of endothelial cells, as well as vessel pruning and remodelling [190].
Endothelium regulates angiogenesis and responds to extracellular factors, such
as vascular endothelial growth factor (VEGF). VEGF regulates proliferation and
survival of endothelial cells, by activating many signalling pathways, including
the mitogen-activated protein kinase (MAPK) and phosphinositide 3-kinase (PI3K)
pathways. On the other hand, angiogenesis can be inhibited as well by extracellular
factors. For example, Notch ligand Delta-like 4 functions to antagonize VEGF
signalling [191]. There are two types of angiogenesis; physiological and pathological.
As opposed to well-functioning vasculature in physiological angiogenesis, the blood
vessels formed by pathological angiogenesis have irregular patterns of branching
and uneven distribution. The new vessels formed by pathological angiogenesis in
conditions, such as wound healing, tumors and atherosclerosis, are also leaky and
hyperpermeable [192].
MicroRNAs (miRNAs), small noncoding RNA molecules that regulate gene
expression at the post-transcriptional level, take part in every step of atherosclerosis
development, including endothelial dysfunction, cellular adhesion, development of
plaques and rupture of plaques [148]. MiRNAs have crucial roles in modulating
angiogenesis as well [193]. The key role of microRNAs as angiogenic signal
transduction pathway modulators has been suggested due to the recently discovered
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miRNAs that are exclusively expressed in endothelial cells [194, 195]. Changes in
expression of microRNAs as a result of growth factor stimulation, or hypoxia also
implicate the role of miRNAs as one of the core components of the angiogenic
signalling [196]. MiRNA regulation of the angiogenic pathways in human disease
states, such as atherosclerosis, remain to be elucidated.
4.1 MiR-126-3p, Spred1 and Pik3r2 expression levels in carotid artery
atherosclerotic plaques
The function of many cells that are part of the cardiovascular system are controlled by
miRNAs, which either regulate vascular homeostasis or contribute to diseases of the
cardiovascular system [197, 198].
The expression of 168 miRNAs were analyzed in human umbilical vein endothelial
cells (HUVECs) by Kuehbacher et al. (2008), with the aim of understanding the role
of miRNAs in functions of endothelial cells. The miRNAs that were found to have high
expression levels in HUVECs included miR-21, miR-126, mir-221, and mir-222 [199].
Fish et al. (2008) have isolated day 7 and day 14 embryoid bodies from mouse
embryonic stem cells and conducted microarray studies for miRNA profiling. They
have demonstrated that several miRNAs including, miR-126, miR-146b, miR-197,
miR-615 and miR-625 were enriched in these cells. Among them, miR-126 was found
to be the miRNA with the highest expression. The expression of miR 126-3p along
with the same set of miRNAs were confirmed in vivo as well, using qRT-PCR and
RNA samples isolated from E10.5 mouse embryos [154].
miR 126-3p is expressed from the intron of Egfl7 [165], which plays a crucial role in
vasculogenesis and angiogenesis [200]. In endothelial cells, angiogenic signalling is
modulated by MiR-126.
Two very important study have demonstrated its crucial role in vessel development.
The first one that was conducted by Fish et al.(2008) have demonstrated the effects of
the loss of function of miR-126 in vitro. In the study, the levels of miR 126-3p and
its passanger strand miR 126-5p were decreased by introducing a morpholino (MO)
antisense to miR-126 to HUVECs. Following transfection, levels of both miRNAs
were decreased, although miR 126-3p basal level was higher compared to its passanger
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strand. In addition, it was observed that the EGFL7 protein levels, encoded by the host
gene of both miRNAs, were not affected. The endothelial cells with decreased levels
of miR 126 had a higher rate of proliferation and the migration of cells in response
to VEGF were inhibited. Knock down of miR 126 affected the formation of stable
capillary tubes in vitro as well. To see the effects of MiR 126 knock down in vivo,
zebrafish fertilized eggs were injected with morpholinos. As a consequence of loss
of miR 126, defective blood vessels and cranial hemorrhages were observed. The
collapsed lumens and defective organization of endothelial tubes revealed in miR-126
morphants suggested the necessity of miR-126 expression for vessel development and
integrity [154].
Wang et al.(2008) investigated miR 126 functions in vivo, by creating miR 126 null
mice. Vascular malformations, such as growth failure of the cranial vessels were
observed in miR 126 null mice. Systemic edema, multifocal hemorrhages and ruptured
blood vessels were present in embryos before they were dead. In addition, decreased
response to angiogenic stimuli, as well as delay in angiogenic sprouting were also
observed [157]. This study suggested the key role of miR 126 for vessel integrity as
well, and led to the further investigation of role of miR 126 in angiogenic signalling.
In the comprehensive study by Fish et al.(2008), many miRNA target prediction
algorithms were used and based on binding sites, some of the predicted targets of
miR 126-3p were validated by cloning parts of their 3 UTR regions into the 3 UTR of
a luciferase construct. Then, in HeLa cells, which do not express miR-126, whether
miR-126 influnces luciferase expression was checked. As a result, miR-126 was found
to target Sprouty-related EVH1 domain-containing protein 1 (SPRED1), vascular cell
adhesion molecule 1 (VCAM1), and regulatory subunit 2 of PI3K (PIK3R2). SPRED1
and PIK3R2 were suggested to negatively regulate endothelial cellular signaling by
affecting the MAPK and PI3K signaling pathways, while MiR 126-3p, by targeting
the negative regulators of VEGF signalling, was suggested to promote angiogenesis. It
was also demonstrated that the knock down of miR 126 constricted the phosphorylation
of ERK and AKT induced by VEGF [154]. To test whether miR-126 was crucial
for the normal endothelial cell response to angiogenic growth factors, Wang et
al.(2008) transfected HUVECs with miR-126 expressing adenovirus and investigated
the activation of MAP kinase by growth factors. The MAP kinase activation was
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detected by phosphorylation of ERK1/2. The phosphorylation of ERK1/2 in response
to growth factors was increased 2-fold by miR-126 expressing adenovirus transfection,
while miR-126 knockdown resulted in decreased ERK phosphorylation [157]. The
findings of Wang et al. and Fish et al. altogether point out to the important role that
miR-126 plays in angiogenic signalling, by increasing MAP kinase activation in VEGF
pathway. The putative model developed by Fish et al.(2008) by the help of their in vitro
studies and in vivo studies in zebrafish is given in Figure 4.1. The model explains how
miR 126-3p aids angiogenesis in endothelial cells via its targets Spred1 and Pik3r2,
the negative regulators of VEGF pathway.
Figure 4.1 : MiR 126-3p and negative regulators of VEGF pathway biogenesis [154].
Based on the hypothesis that vascular cell adhesion molecule 1 (VCAM1) expression
and vessel inflammation is regulated by a miRNA, Harris et al.(2008) have set
out to investigate the miRNA expression profile of endothelial cells via microarray.
Alongside with the studies of Fish et al. and Wang et al., they too have demonstrated
that HUVECs were enriched with miR 126 the most. Using bioinformatic analysis,
they have demonstrated that VCAM1 was targeted by miR 126-3p and verified the
predicted miR 126-3p target by luciferase assays. When endogenous miR 126-3
levels were decreased in endothelial cells and cells stimulated with tumor necrosis
factor- α (TNF-α), expression of VCAM-1 increased. On the other hand, VCAM-1
expression was observed to decrease in respnse to overexpression of miR-126. In
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addition, diminished levels miR-126 resulted in an increase in adherence of leukocytes
to endothelial cells. All together, their results suggest a miRNA modulation of
inflammation in atherosclerosis [201].
Following their study published in 2008, in which they had demonstrated the role of
miR 126-3p in inflammation through VCAM1, Harris et al.(2010) investigated the
roles of E26 transformation-specific sequence (ETS) factors, members of a family
of transcription factors that take are known to be expressed in endothelial cells and
take part in processes, including vessel formation, remodelling and inflammation. By
cloning an upstream regulatory region of the Egfl7/miR-126 locus into a luciferase
expression plasmid and transfecting the construct into a variety of endothelial
cells, such as HUVECs and human aortic endothelial cells (HAECs), and into
non-endothelial cells, they performed luciferase assays. It was observed that the
upstream regulatory region of Egfl7/miR-126 locus, which preserves an Ets binding
site, was crucial for transactivation of miR-126 host gene, Egfl7. Many members of
ETS family were over-expressed in endothelial cells, with the aim of finding the family
members that take part in regulating miR-126 expression. Their data revealed that
ETS-1 and ETS-2 take part in regulation of miR-126 expression [202].
Kruppel-like factor 2 (KLF2), a member of the zinc finger family of transcription
factors taking part in regulation of processes, such as development and differentiation
[203], was found to transcriptionally regulate miR-126 by Nicoli et al.(2010). On the
other hand, Hergenreider et al.(2012) observed in adult endothelial cells that shear
stress induced KLF2 did not function to augment miR-126 levels [204, 205].
It has been shown by various studies that angiogenesis is boosted by different
population of cells derived from peripheral blood mononuclear cells (PBMC). Cells
with different surface markers, identified by the use of cluster of differentiation
(CD) system, are separated as different subpopulations. CD34+ or CD14+ surface
expression differences have been widely utilized for separation of the PBMC
subpopulations [206–208]. Specifically, it has been demonstrated that CD34+ PBMCs
help angiogenesis during ischemic conditions [209, 210]. In the study performed
by Mocharla et al.(2013), differential miRNA expression profiles of CD34+ /CD14+,
CD34+ /CD14-, CD34- /CD14+ and CD34- /CD14- PBMC subsets was investigated.
In comparison to CD34- subsets, CD34+ subsets displayed more proangiogenic
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properties. In the supernatants of CD34+ subsets of PBMCS, miR 126 expression was
higher. MiR 126 was shown to be secreted in microvesicles. MiR 126 expression in
CD34+ PBMC fractions of diabetic patients was diminished, leading to the conclusion
that the proangiogenic properties of endothelial progenitor cells was abolished in
diabetes [211].
Similar studies have been done demonstrating the effects of Diabetes on functions
of endothelial progenitor cells which take part in endothelial damage repair. Meng
et al.(2012) have provided evidence on the effect of the downregulation miR-126 in
endothelial progenitor cells obtained from diabetic patients. Their study has shown
that, through its target, SPRED1, miR 126 disrupts the endothelial progenitor cell
mediated function [212]. Jansen et al.(2012) have shown in vivo, that endothelial
microparticles (EMPs)released from endothelial cells undergoing apoptotis have roles
in endothelial repair after vascular injury. The EMPs were assessed for their miRNA
content and the highest miRNA expression level was observed with miR 126. It
was found that the transport of miR-126 was accomplished by EMP. When diabetic
conditions were simulated in vitro, the miR 126 levels of EMPs were found to
be lower and the capacity of the EMPs to repair endothelial damage was reduced.
Same results were obtained when circulating EMPs obtained from 176 coronary
artery disease patients with and without diabetes were investigated for their miR 126
expression levels [213]. From all the studies reviewed above, it can be concluded
that miR 126 plays an atheroprotective role. In the review by Chistiakov et al.(2016),
miRNA up-regulation is suggested to enhance angiogenesis by recruiting endothelial
progenitor cells to sites with endothelial damage, as a response to vascular injury and
ischemic conditions caused by atherosclerosis [153].
While miR 126-3p has atheroprotective roles in endothelial cells under physiological
conditions, it has been shown by Zhou et al.(2013) to contribute to formation of
neointima in vascular smooth muscle cells (VSMCs) in co-cultures with endothelial
cells. Mir 126-3p displayed its pro-atherosclerotic affects by increasing the apoptosis
and proliferation of VSMCs [214]. A potential function of miR 126-3p was suggested
in the arterial remodelling observed in advanced atherosclerosis. Up-regulation of miR
126-3p in the intra-plaque regions due to the hypoxic conditions and static flow inside
these regions, is suggested to trigger neoangiogenesis inside atherosclerotic plaques,
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as well as proliferation and migration of VSMCs [153]. This thesis study provides the
first evidence on miR 126-3p expression in deep intraplaque regions.
Although it has been identified an an angiomiR, miR 126-3p was studied in cell
culture or in model organisms, such as Zebrafish or mice. Of the very limited
studies performed on samples obtained from cardiovascular disease patients, Tampere
Vascular Study conducted by Raitoharju et al.(2011) is of importance. In this study,
the miRNA expression profile in 12 human carotid, femoral and coronary artery
atherosclerotic plaques was investigated and compared to 6 control arteries. MiR-21,
-34a, -146a, -146b-5p, and -210 expression levels were found to be significantly
up-regulated [215]. In the study by Fichtlscherer et al.(2010), 36 coronary artery
disease patients and 17 healthy controls were investigated for the levels of circulating
miRNAs. Of the 10 endothelial specific circulating miRNAs, miR 126 was observed
to be down-regulated in coronary artery disease patients and in coronary artery disease
patients with Diabetes, compared to healthy controls [216].
In the present thesis study, the expression levels of miR 126-3p and its targets, Spred1,
Pik3r2 and Egfl7 have been evaluated in human carotid artery atherosclerotic plaques
and controls. To the knowledge, this study is the first to evaluate the expression levels
of miR 126-3p, its targets Spred1, Pik3r2 and its host gene Egfl7 in atherosclerotic
plaques from human carotid arteries. It was hypothesized that the expression levels
of miR 126-3p would be higher in atherosclerotic plaques, as an indicator of ongoing
neoangiogenesis in the plaques, while the negative regulators of the VEGF pathway
would be down-regulated, due to miR 126-3p mediated repression.
As expected, miR 126-3p expression was higher in 11 out of 14 atherosclerotic plaque
samples compared to plaque adjacent controls. Spred and Pik3r2 were down-regulated
in 8 and 9 samples compared to controls, respectively. Considering the overall gene
expression levels, miR 126-3p was up-regulated 2.14 fold in plaques in comparison
to controls, while Spred1 and Pik3r2 were also up-regulated by 0.18 and 0.22 fold,
respectively.
The correlation of cardiovascular disease risk factors with gene expression levels were
investigated, with the aim of determining the factors that affect the levels of miR
126-3p and its targets. Mir 126-3p up-regulation was observed in 88.9 % of female
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patients, in 71.4% of smokers, in 75% of patients with a family history of cardivascular
disease, in all of the diabetic patients, in 81.8% of hypertensive patients, in 88.9%
of patients who have had a cerebrovascular event, in 60% of the patients who have
coronary artery disease as well and in all of the patients with peripheral artery disease.
The only significance correlation, though, was found between up-regulation of Pik3r2
and high low-density cholesterol levels(p=0.044).
Larger study groups are needed to confirm these data, since the analysis of single
risk factors (such as diabetes or coronary artery disease) is impeded by the relatively
small numbers of patients. In addition, underlying molecular mechanisms of
miR 126-modulated dysregulation need further investigation, particularly on the
phosphorylation status of the downstream signalling molecules, including AKT and
ERK, to be able to fully grasp the affect of miR-126 on VEGF regulated angiogenesis
in atherosclerosis. The interaction of miR-126 with other miRNAs and signalling
molecules needs to be elucidated. Furthermore, larger scale studies must be performed
on more than one arterial system, with the aim of determining the specif regulation of
angiogenesis by miRNAs in different arterial systems. The potential use of miRNAs as
biomarkers to monitor plaque neoangiogenesis and disease progression, as well as the
development of miRNA-based therapies are promising areas of research in the battle
against the fatal consequences of atherosclerosis.
4.2 MiR-126-5p expression in carotid artery atherosclerotic plaques
What leads to initiation of atherosclerosis and its progression remain to be elucidated.
However, endothelial dysfunction plays a key role in the initiation of atherosclerotic
process. The arterial branching sites, where there is disturbed laminar flow,
are susceptible to endothelial dysfunction, therefore plaque formation [56, 217].
Endothelial cells need laminar flow derived shear stress for differentiating into their
specific phenotype, which is non-replicative [218–220]. MiRNAs, in addition to their
many other functions, have been investigated for their roles in shear stress. MiR 126-3p
has been studied widely and named as an angiomiR, while there are not many studies
focusing on the role of its passanger strand, miR 126-5p.
In the comprehensive study by Schober et al.(2014), it was shown in rats that
in response to injury, high miR-126-5p levels were needed for the regeneration
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of endothelial cells. It was demonstrated that miR-126-5p executes its effect by
suppressing Delta like ligand 1 (Dlk1). DLK1 is suggested to damage angiogenesis
by inhibiting NOTCH1 activation [221]. The role of non-canonical NOTCH ligand
DLK1 as an angiogenesis inhibitor had been demonstrated previously by Rodriguez et
al.(2012). They have demonstrated in many models and organisms, including bovine
aortic endothelial cells, porcine aortic endothelial cells, mouse lung endothelial cells,
HUVECs, zebrafish and mice, that DLK1 functions as an antiangiogenic molecule
via NOTCH pathway [222]. In addition to this non-canonical NOTCH ligand, three
canonical ligands, JAGGED 1, DLL1, and DLL4, are known to take on important
tasks in angiogenesis in endothelial cells [223]. It was demonstrated by many studies
that whenever DLL44 is in, NOTCH pathway functions to inhibit angiogenesis [126].
Rodriguez et al. mentioned in their study that the interplay between these canonical
NOTCH ligands and the non-canonical ones are complex, therefore requires further
investigation. In the study of Schober et al., the impaired angiogenesis results in
increased cell permeability and in increased influx of low-density lipoprotein into
the vessel wall, causing atherosclerotic lesion formation. It was observed that high
levels of miR-126-5p in endothelial cells localized in non-predilection sites resulted in
endothelial cell proliferation which managed to overcome the anti-proliferative effects
caused by hyperlipidemia, while downregulation of miR-126-5p via upregulation of
Dlk1 in sites with the disturbed flow prevented proliferation of endothelial cells in the
hyperlipidemic conditions [221]. At normal arterial sites with laminar blood flow,
apoptosis of endothelial cells is limited, therefore endothelial cells do not require
proliferation [224]. On the other hand, to be able to keep the endothelial monolayer
intact, proliferation of endothelial cells is needed at predilection sites with turbulent
flow. Upon disturbed laminar flow, miR 126-5p is suggested to be down-regulated,
causing a decrease in the proliferation of endothelial cells residing in such areas. This
conditions is worsened in hyperlipidemic conditions [225]. Therefore, expression of
miR 126-5p is suggested to have a protective role against endothelial injury [221]. The
putative model explaining the atheroprotective effects of miR 126-3p and -5p reviewed
by Boon and Dimmeler (2014) is shown in Figure 4.2 [226].
The role of miR 126-5p in leukocyte adhesion and trafficking was investiged in
HUVECs and in mice by Poissonnier et al.(2014). In the study, it was shown that
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Figure 4.2 : MiR 126-3p, miR 126-5p and their suggested atheroprotective
roles [226].
expression of miR126-5p was highest in blood vessels both in vivo and in vitro. The
new roles of promoting adhesion of leukocytes and repressing their transendothelial
migration were assigned to miR 126-5p via knock out and over-expression of the
miRNA in HUVECs. The activated leucocyte cell adhesion molecule (ALCAM),
encoding an adhesion molecule that takes part in leucocyte transendothelial migration
and SetD5 gene with no assigned functions were discovered as novel targets of miR
126-5p. By regulating SetD5 and Alcam, miR 126-5p was suggested to aid in leucocyte
adhesion and to repress transendothelial migration, respectively [227].
In this study, which provides the first evidence on the expression levels of miR 126-5p
and its host gene, Egfl7 in human carotid artery atherosclerotic plaques and controls,
the levels of miR 126-5p expression were evaluated using real time quantitative PCR
and relative gene expression strategy. It was hypothesized that together with its
passenger strand miR 126-3p, miR 126-5p would be up-regulated in atherosclerotic
plaques due to the intraplague angiogenesis, a hallmark of advanced atherosclerosis.
MiR 126-5p was found to be up-regulated in eight patient plaque samples compared
to controls, while down-regulation was observed in six of the patient samples.
Considering the overall expression, miR 126-5p expression was higher in plaques
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compared to control samples. Moreover, to determine the cardivascular risk factors
that influence miR 126-5p expression levels, the correlation between the cardiovascular
disease risk factors and gene expression levels were investigated. While performing
these analyses, the patients samples were split into two groups; plaque samples with
low and high miR 126-5p expression levels. The samples with relative expression fold
change values above 0.82 were considered in the high expression level group. Risk
factors, including being female, BMI ≥ 25, smoking, family history of cardiovascular
diseases, hypertension, Diabetes, presence of a cerebrovascular event, coronary artery
and peripheral artery disease were not significantly correlated with miR 126-5p
expression levels. However, a positive correlation was found between high levels of
LDL cholesterol and upregulation of miR-126-5p (p=0.023). The positive correlation
between high levels of LDL cholesterol and high levels of miR 126-5p, therefore
increased angiogenesis can be explained by the role of lectin-like oxidized low-density
lipoprotein receptor-1 (LOX-1) in angiogenesis. LOX-1 is the receptor for facilitation
of uptake of oxidized low density lipoprotein [228]. Recently, Jiang et al.(2011) have
associated LOX-1 with angiogenesis [229]. High levels of LDL cholesterol could be
attributed to LOX-1 up-regulation, which also plays a role in angiogenesis, though
further investigation is required for linking the angiogenesis related up-regulation of
miR-126 to LOX-1 expression.
Carotid artery plaque samples were surgically removed from different locations,
and the locations of the plaques is an important parameter, since atherosclerotic
plaques are observed more frequently in sites with disturbed laminar flow. The
differences in expression levels of miR-126-5p could be attributed to the fact that
plaques were removed from sites with high shear stress as opposed to non-predilection
sites. Furthermore, the degree of narrowing (stenosis) in the carotid artery is another
parameter affecting the expression of miR 126-5p, since miR-126 expression is highly
influenced by vascular injury. Further investigations with larger patient samples
are needed. Patient samples must be studied considering the different degrees
of stenosis, to be able to fully understand the roles of angiogenesis in different
stages of atherosclerosis. Moreover, Dlk1 levels need to be assessed together with
miR-126-5p expression in healthy tissues and in atherosclerotic plaques removed from
high-shear-stress or non-predilection sites, since these studies have not been conducted
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in samples from patients with cardiovascular diseases. Such studies would aid in
better understanding of the molecular mechanisms of angiogenesis regulation via miR
126-5p and its targets.
4.3 Egfl7 expression in carotid artery atherosclerotic plaques
Egfl7 was first identified as a novel gene by Fitchet al.(2004). They have demonstrated
in mice that Egfl7 expression begins in early stages of embryonic development, and
is restricted to vascular tissues and endothelium in adults [230]. Following this study,
the same research group, including Campagnolo et al.(2005), have investigated the
expression patterns of Egfl7 in the adult vasculature, such as the pregnant uterus, and in
two different arterial injury models. Egfl7 expression was observed to be exclusive to
the endothelium. Up-regulation of Egfl7 was shown in the pregnant uterus, where there
is increased angiogenesis. In addition, up-regulation was demonstrated in response to
vascular injury, both in the balloon injury models in rats and the ferric chloride injury
model of mouse carotid arteries [165].
The relationship between Egfl7 and miR 126 was discovered by the study of Kuhnert
et al.(2008), in which deletion of MiR-126 in mice (without altering Egfl7 expression)
caused major defects in blood vessel development, such as delays in angiogenesis,
haemorrhage and early embryonic lethality [156]. As reviewed by Nikolic, Plate and
Schmidt (2010), Egfl7 encodes miR 126-3p and -5p, along with the 30 kD protein
specific to vascular endothelium. In contrast to its high levels of expression during
development, Egfl7 is downregulated in the vascular system with birth and kept at
low levels only in vessels on the lung, heart, kidney, spleen and uterus under normal
physiological conditions. In tissues that require high levels of angiogenesis, such
as uterus during pregnancy, or in conditions of pathological angiogenesis, including
neoangiogenesis in atherosclerosis or tumor angiogenesis, Egfl7 is up-regulated in
adults [160].
As strongly suggested by the data available, EGFL7 functions as a suppressor of
NOTCH activity in the endothelium, which negatively regulates the proliferation
of endothelial cells and inhibition of endothelial cell sprouting [231]. Nichol et
al.(2010) have over-expressed Egfl7 in transgenic mice and observed partial lethality
and hemorrhaging in mice as a consequence of the over-expression of Egfl7. The
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defects observed were suggested to be resulting from excessive angiogenesis. On
the other hand, in human primary endothelial cells, the knockdown of Egfl7 had an
inhibitory effect on endothelial cell proliferation, sprouting, and migration, as a result
of NOTCH inhibition. Their results provided evidence on the physical interaction of
EGFL7 and NOTCH, suggesting the inhibitory role of EGFL7 on NOTCH activity
[161].
The expression of miR-126 host gene, Egfl7 was studied together with miR 126-3p,
miR 126-5p, Spred1 and Pik3r2 in human carotid atherosclerotic plaques in this thesis
work. To the knowledge, this study represents the first report to assess the levels of
Egfl7 and miR-126-5p in human carotid atherosclerotic plaques.
Egfl7 expression is exclusive to the endothelium. EGFL7 acts only on endothelium and
plays key roles in angiogenesis. It was hypothesized that Egfl7 would be up-regulated
in atherosclerotic plaques in response to the vascular injury caused by progressive
atherosclerosis. As expected, Egfl7 up-regulation was observed in eleven plaque
samples out of fourteen.
Although the role of new blood vessel development within advanced atherosclerotic
plaques remains to be understood, its presence in advanced atherosclerosis is
considered as a marker of ongoing disease activity and a factor that produces high-risk
plaques. Neo-angiogenesis causes stenosis, hemorrhage and thrombosis within the
plaques, contributing to atherosclerosis progression. Conversely, an atheroprotective
role for neo-angiogenesis was proposed. The proangiogenic miRNAs, cytokines
and endothelial progenitor cells play roles in the repair of the endothelium via
angiogenesis. Despite the opposing roles of Egfl7, its higher expression levels could
possibly be contributing to disease progression via boosting neo-angiogenesis in
diseased vessels, which is already a hallmark of atherosclerosis.
Further studies elucidating the role of Egfl7 in pathological angiogenesis might
potentially help atherosclerotic plaque regression and stabilize vulnerable plaques in
order to prevent the devastating effects of thrombosis. In addition, Egfl7 can be
considered as a promising prognostic marker of intraplaque neoangiogenesis, therefore
aid in monitoring the unstable plaques, as well as preventing vulnerable plaque rupture.
Moreover, Egfl7 based anti-angiogenesis therapy could be offered as a promising
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strategy in eliminating intraplaque neoangiogenesis, and stabilization of plaques that
are prone to rupture, therefore preventing the devastating consequences of advanced
atherosclerosis.
4.4 The use of microRNAs as prognostic biomarkers atherosclerosis
An molecule that is to be used as a biomarker must be expressed in high levels in the
tissue of interest. It needs to be present at low concentrations in the blood and other
body fluids as well [233,234]. These biomarkers are released into the blood following
tissue injury, therefore their detection is facilitated via a blood-based assay [235, 236].
For example, biomarkers used to diagnose heart disease, such as creatine kinase–MB
isoenzymes and cardiac troponins, have been developed via targeted analyses of
myocardial proteins [237]. For diagnosing acute myocardial infarctions and prognosis
after coronary artery bypass surgery, cardiac troponins are the ‘gold standard’ [238].
It was shown by many studies that biomarkers are valuable tools for monitoring
progression of atherosclerosis. Such widely used biomarkers include, proinflammatory
biomarkers or biomarkers of plaque destabilization and rupture, which are very
important in prediction of up-coming cardiovascular events. Some of the biomarkers
which are under investigation include, c-reactive protein, cytokines interleukin 6
(IL-6) and IL-8, oxidized LDL, glutathion peroxidase, myeloperoxidase, matrix
metalloproteinases and monocyte chemoattractant protein-1 [239].
The role of miRNAs in cardiovascular development and modulation, as well as in
diseases of the vascular system has been highlighted by several studies. In the recent
years, the functions of miRNAs in the regulating vessel biology and pathophysiology
have been widely investigated [240]. Currently research suggests the use miRNAs as
sensitive and early biomarkers for cardiovascular diseases. MiRNA expression is often
specific to tissues. They represent high sensitive and specific biomarkers, because they
can be detected by real-time PCR. Furthermore, there is evidence that upon tissue
injury, they are released into blood stream via microvesicles, therefore they can be
found in circulation at consistent and reproducible levels [241]. However, their low
amount in blood constitutes a problem in concentration and quality measurements,
therefore is a challenge that needs further work [242].
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The miRNAs 126-3p and -5p, as well as their host gene Egfl7 can be considered
as promising prognostic markers for monitoring neoangiogenesis in advanced
atherosclerosis. Further work investigating the levels of circulating miR 126-3p and
miR 126-5p in peripheral blood of patients with cardiovascular diseases is needed to
assess the use of these circulating miRNAs as biomarkers for advanced atherosclerotic
disease.
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5. CONCLUSIONS
Cardiovascular diseases are the leading cause of death in the world and in our
country today. The underlying pathological condition of cardiovascular diseases is
atherosclerosis.
Atherosclerosis is the chronic, progressive and immunoinflammatory disease of the
medium- and large-size arteries. It is a complex disease which involves interactions
of multiple genetic and environmental factors. Starting with birth, atherosclerotic
process progresses slowly, causing diseases, such as coronary artery disease, stroke,
peripheral artery disease. In the inflammatory process of atherosclerosis, the outer
layer of arteries, the intima layer, gets thicker with lipid rich material (atheroma)
and connective tissue (sclerosis). According to the "Response to Injury" hypothesis
of atherosclerosis, potential sources of injury, such as hyperlipidemia, hypertension,
metabolites, infections and mechanical factors such as shear stress are suggested to
cause the initiation of atherosclerosis. The pathological changes in atherosclerosis
occur due to molecular events of endothelial dysfunction, monocyte adherence and
entry into the vessel wall, monocyte development into foam cells, smooth muscle
cell migration and proliferation, advanced plaque formation with necrotic core and
neoangiogenesis, and thrombosis as a result of plaque rupture. Following rupture of a
vulnerable plaque, thrombus formation resulting in stroke or a myocardial infarction
causes deaths or disabilities. Atherosclerosis would possibly be a more benign disease
if thrombus formation could be prevented. The investigation of molecular mechanisms
resulting in angiogenesis in advanced plaques, a hallmark event of atherosclerosis, has
been the main focus of this thesis study.
Angiogenesis is the process of new vessel formation from existing ones. The main
signalling pathways that control angiogenesis in cells are the vascular endothelial
growth factor (VEGF) pathway and Notch signalling. Intraplaque neoangiogenesis
has been linked with progressive atherosclerotic disease. The signalling pathways
contributing to angiogenesis represent potential targets for therapies aiming to prevent
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intraplaque neoangiogenesis. This thesis study focuses on the role of angiogenic
mechanisms related to vascular endothelial growth factor pathway and the mechanisms
that interact with this pathway, such as microRNAs, the small, non-coding RNAs that
post-transcriptionally regulate many cellular processes, including angiogenesis. Egfl7,
a major player of angiogenesis that is expressed exclusively in embryonic and adult
vasculature, encodes two endothelial-specific miRNAs: miR 126-3p and miR 126-5p.
This thesis study was conducted with the aim of understanding the role of miR-126
signalling in angiogenesis and its contribution to carotid artery disease progression.
For this purpose, the expression levels of miR 126-3p, the targets of miR 126-3p, miR
126-5p and Egfl7 were investigated in 14 human carotid artery atherosclerotic plaques
and control samples.
The results have shown higher miR 126-3p expression in 11 out of 14 atherosclerotic
plaque samples compared to plaque adjacent controls. Spred and Pik3r2 were
down-regulated in 8 and 9 samples compared to controls, respectively. Considering
the overall gene expression levels, miR 126-3p was up-regulated 2.14 fold in plaques
in comparison to controls (p <0.05). MiR 126-5p was found to be up-regulated in eight
patient plaque samples compared to controls, while down-regulation was observed in
six of the patient samples. Considering the overall expression, miR 126-5p expression
was higher in plaques compared to control samples. Egfl7 up-regulation was observed
in eleven plaque samples out of fourteen. The overall Egfl7 mRNA expression was
higher in plaques (p <0.001) compared to controls.
This work, supported by data on expression levels of miR 126-5p, miR 126-3p and its
targets Spred1, Pik3r2 and Egfl7, demonstrates the contribution of miR-126 signalling
molecules and neoangiogenesis driven by these molecules to atherosclerotic plaque
progression in advanced atherosclerosis, despite their known atheroprotective roles
in endothelial progenitor cells. This thesis study provides the first evidence on miR
126-3p expression in deep intraplaque regions. To the knowledge, the expression levels
of miR 126-3p, its targets Spred1, Pik3r2, miR 126-5p and Egfl7 in atherosclerotic
plaques from human carotid arteries were evaluated for the first time.
The molecular mechanisms of miR 126-modulated dysregulation need further
investigation, particularly on the phosphorylation status of the downstream signalling
molecules, to be able to fully grasp the affect of miR-126 on vascular endothelial
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growth factor regulated angiogenesis in atherosclerosis. The interaction of miR-126
with other miRNAs and signalling molecules needs to be elucidated. To be able to
fully understand the roles of angiogenesis in different stages of atherosclerosis, the
study of patient samples considering the different degrees of stenosis is suggested.
Furthermore, larger scale studies must be performed on more than one arterial system,
with the aim of determining the specific regulation of angiogenesis by miRNAs in
different arterial systems.
The potential use of miRNAs as biomarkers to monitor plaque neoangiogenesis
and disease progression, as well as the development of miRNA-based therapies
are promising areas of research in the battle against the fatal consequences of
atherosclerosis. The results of this thesis study constitutes preliminary bases for future
miRNA biomarker studies to be used in monitoring plaque progression and intraplaque
neoangiogenesis. The miRNAs 126-3p and -5p, as well as their host gene Egfl7 can
be considered as promising prognostic markers for monitoring neoangiogenesis in
advanced atherosclerosis. Further work investigating the levels of circulating miR
126-3p and miR 126-5p in peripheral blood of patients with cardiovascular diseases
is needed to assess the use of these circulating miRNAs as biomarkers for advanced
atherosclerotic disease.
The results of miRNA expressions in atherosclerotic plaques also provide useful
information that can lead to future miRNA based therapies for preventing intraplaque
neoangiogenesis, therefore thrombosis. In addition, Egfl7 can be considered as a
promising prognostic marker of intraplaque neoangiogenesis, to aid in monitoring
the unstable plaques, as well as preventing vulnerable plaque rupture. Egfl7 based
anti-angiogenic therapy could be offered as a strategy in eliminating intraplaque
neoangiogenesis and stabilization of plaques that are prone to rupture, therefore
preventing the devastating consequences of advanced atherosclerosis.
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APPENDIX A: Chemicals and Commercially Available Kits
Table A.1 : Chemicals and Commercially Available Kits.
Name Brand Supplier
mirVana miRNA Isolation Kit with phenol Ambion MedSanTek
High Capacity cDNA Reverse Transcription Kit Applied Biosystems MedSanTek
TaqMan R© MicroRNA Reverse Transcription Kit Applied Biosystems MedSanTek
TaqMan R© Universal PCR Master Mix, 2-pack Applied Biosystems MedSanTek
Ultrapure DNASE/RNASE-Free Water Applied Biosystems MedSanTek
TaqMan R© MicroRNA Assay, hsa-miR-126-3p Applied Biosystems MedSanTek
TaqMan R© MicroRNA Assay, hsa-miR-126-5p Applied Biosystems MedSanTek
TaqMan R© MicroRNA Assay, U6 snRNA Applied Biosystems MedSanTek
TaqMan R© Gene Expression Assay, SPRED1 ThermoFisher Scientific MedSanTek
TaqMan R© Gene Expression Assay, PIK3R2 Applied Biosystems MedSanTek
TaqMan R© Gene Expression Assay, EGFL7 Applied Biosystems MedSanTek
TaqMan R© Gene Expression Assay, 18S Applied Biosystems MedSanTek
RNaseZap Sigma-Adrich LABOMED
Ethanol Absolute Merch LABOMED
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APPENDIX B: TaqMan R© Assay ID Numbers
ID numbers of the commercially available TaqMan R©miRNA and Gene Expression
Assays are as follows:
• miRNA 126-5p: 000451
• miRNA 126-3p: 002228
• U6 snRNA: 001973
• SPRED1: Hs01084559_ m1
• PIK3R2: Hs00178181_ m1
• EGFL7: Hs00211952_ m1
• 18S: Hs99999901_ s1
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APPENDIX C: Laboratory Equipment
Table C.1 : Laboratory Equipment.
Name Brand-Model
Analytical Balance Precisa LT120A
Micropipettes Eppendorf R© Research Plus 4-pack
Vortex mixer Scilogex MX-S
Microcentrifuge ThermoFisher Scientific Eppendorf R© 5424
Thermomixer ThermoFisher Scientific Eppendorf R© Comfort
Spectrophotometer ThermoFisher Scientific Nanodrop 2000
Thermal Cycler Bio-Rad T100
Refrigerator Arçelik 4263
Freezer Arçelik 2052 DY
Ultra Low Freezer VWR R© Symphony
qPRC System Agilent Mx3005P
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